BIBA Publishing
Sudden cardiac death higher in men with slower electrical impulses through...
A Finish study has found that men whose electrical impulses take a few milliseconds longer to travel through the lower chambers of the heart had an increased risk of sudden cardiac death.
UK’s NICE releases final guidance on rivaroxaban for prevention of stroke...
The guidance recommends rivaroxaban for people with non-valvular atrial fibrillation who have one or more risk factors such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke or transient ischaemic attack.
Nominal ICD settings are “probably too conservative”
Data presented at HeartRhythm 2012 on the ADVANCE III trial have shown that a greater number of intervals to detect arrhythmias significantly reduces unnecessary implantable cardioverter defibrillator (ICD) therapy.
Subcutaneous defibrillator is safe and effective
Lead author Martin Burke, University of Chicago Hospitals, USA, presented a study at HeartRhythm 2012 that showed the subcutaneous implantable cardioverter defibrillator (S-ICD) to be an effective treatment for patients with ventricular tachyarrhythmias.
“Blanket ban” on sports in people with implantable cardioverter defibrillators is...
A study presented by Rachel Lampert, New Haven, USA, at HeartRhythm 2012 (9-12 May, Boston, USA) shows that sports participation of patients with an implantable cardioverter defibrillator (ICD), in many athletes, is not associated with any serious adverse events.
Data presented at HRS 2012 suggest Convergent Procedure ablation may restore...
nContact has announced that new long-term physician data demonstrated promising clinical outcomes for the multidisciplinary Convergent Procedure in the treatment of persistent atrial fibrillation (AF), with over 80% of patients remaining in sinus rhythm at a minimum of 12 months follow-up.
Palpitations are predictive of future atrial fibrillation
A large cohort study from Norway has found that the strongest risk factors for atrial fibrillation in both men and women were a history of palpitations and hypertension.
Anne Gillis: new president of the Heart Rhythm Society
The announcement was made at the Presidents' Reception on Friday 11 May. Gillis now serves as the 34th president of HRS and the second international president preceded by Bernard S Goldman, (1982-1983).
Watchman device shows 75% reduction in stroke risk in patients with...
Vivek Reddy, New York, USA, presented results from the ASA Plavix (ASAP) study of the Watchman Left Atrial Appendage Closure (LAAC) device (Boston Scientific) during a late-breaking session at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston, USA.
RAFT trial shows CRT-D therapy is cost-effective for mildly symptomatic heart...
An economic analysis of the RAFT trial showed a US$33,025 cost per Quality Adjusted Life Year (QALY) gained using Medtronic CRT-Ds in a mild, New York Heart Association (NYHA)-designated Class II-III heart failure patient population.
First ICD implantation performed for ESCAPE-ICD registry in Latin America
ESCAPE-ICD is a large-scale observational study, sponsored by Biotronik, designed to tackle the alarming lack of data on sudden cardiac death in Latin America.
Boston Scientific introduces ICD and CRT-D device warranties of up to...
Boston Scientific has announced extended warranties of up to 10 years, depending on the model, for its Energen and Incepta implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy defibrillators (CRT-Ds).
Biosense Webster introduces the Thermocool SF NAV catheter with Curve Visualization...
The Thermocool SF NAV catheter is designed to reduce fluoroscopy exposure to physicians, lab staff and patients alike, enhance visualisation of the ablation catheters orientation and improve procedural efficiency.
Cameron Health’s S-ICD System meets primary safety and efficacy endpoints in...
Martin C Burke, University of Chicago, USA, presented the results of the S-ICD System investigational device exemption clinical trial at a late-breaking session at the Heart Rhythm Society's 33rd Annual Scientific Sessions (9-12 May, Boston, USA).
Symposium on epicardial approach to posterior cardiac ablation convened at Heart...
Electrophysiology thought leaders gathered to discuss the significance of posterior ablation in the treatment of arrhythmias, with presentations highlighting the importance of isolating the posterior left atrium with an adjunctive epicardial treatment.
FDA approves Ellipse ICD
The Ellipse implantable cardioverter defibrillator (St Jude Medical) is the industry's smallest high-energy ICD and it has been designed with feedback from more than 200 physicians from around the world
Stereotaxis technology to be showcased at the Heart Rhythm Society annual...
Stereotaxis has announced that a total of 11 invited podium presentations will feature the use of Stereotaxis magnetic navigation technology in a wide variety of arrhythmias.
Boston Scientific gets FDA approval for new devices to treat bradycardia
The FDA has approved the Ingenio and Advantio pacemakers and Invive cardiac resynchronisation therapy pacemakers (CRT-P).
Worldwide multicentre experiences with HeartLight EAS to be presented at Heart...
CardioFocus has announced that its HeartLight Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation will be highlighted both as part of the scientific sessions and during a private academic symposium at the Heart Rhythm Society's 33rd Annual Scientific Sessions (9-12 May, Boston, USA).
Biotronik to showcase world’s first ICD, CRT-D and CRT-P devices with...
Biotronik will showcase the Lumax 740 ICD and CRT-D series and the Evia HF-T with ProMRI, a technology that allows patients requiring tachycardia and heart failure therapies to have access to magnetic resonance imaging.
Non-surgical procedure offers patients with atrial fibrillation who cannot take blood...
The procedure, known as left atrial appendage occlusion, is performed using the FDA-approved Lariat Suture Delivery Device (SentreHeart).
Preliminary results of largest study comparing warfarin and dabigatran announced
Initial findings from the "Dabigatran in the real world" study reveal that complications necessitating therapy discontinuation occurred more frequently with dabigatran than with warfarin.
“The future of AF ablation catheter technologies”: A new report reveals...
Design and technology consultancy Cambridge Design Partnership has announced that it has completed a research project to identify the future of medical technology to treat atrial fibrillation.
Heart Rhythm Society launches atrial fibrillation and sudden cardiac arrest awareness...
The Heart Rhythm Society (HRS) has launched a Boston citywide awareness campaign to increase knowledge about symptoms, warning signs and available treatment options for atrial fibrillation and sudden cardiac arrest.
Spectranetics receives FDA approval for advanced GlideLight laser sheath
GlideLight requires 55% less force to advance in the removal of cardiac leads than the existent SLS II laser sheath (Spectranetics).
Biotronik announces European launch of Evia HF-T pacemaker series
Evia HF-T is the first cardiac resynchronisation therapy (CRT-P) device approved for use in an MRI environment.
Biotronik announces first implantation of Lumax 740 ProMRI ICD in Asia
After the international launch on 17 April 2012, the first device implantation of a Lumax 740 ICD in Asia was successfully performed by Jeffrey Wing-Hong Fung, director of Electrophysiology Laboratory at Hong Kong Adventist Hospital.
Stroke risk high when anti-clotting drugs stopped
Some patients with certain types of atrial fibrillation who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging Science Series webinar.
Defibtech Introduces TSO-authorised aviation battery for Lifeline View AED
The long-life battery provides for eight hours of continuous operation to monitor and document a patient's ECG during a flight, and to provide defibrillation shocks as required.
Radiofrequency catheter ablation is safe and effective in the octogenarian patient...
A study published in the Journal of Cardiovascular Electrophysiology shows that catheter ablation of octogenarians with atrial fibrillation is as safe and effective as catheter ablation of atrial fibrillation in younger patients
Catheter ablation of ventricular tachycardia in patients with ARVD/C significantly reduces...
A new study, published in Circulation: Arrhythmia and Electrophysiology, indicates that catheter ablation of ventricular tachycardia is an important treatment option in patients with ARVD/C, despite a high rate of ventricular tachycardia recurrence, because it reduces the burden of the arrhythmia
Implantable cardioverter defibrillators in patients nearing the end of life
Rachel Lampert, New Haven, USA, is giving the talk "When to consider ICD deactivation: End-of-life issues" at Heart Rhythm 2012 (9-12 May 2012, Boston, USA). She talked to Cardiac Rhythm News about this topic.
Hugh Calkins
Hugh Calkins, chair of the upcoming Heart Rhythm 2012─Scientific Sessions Program Committee, spoke to Cardiac Rhythm News about his career highlights, Heart Rhythm 2012, and the new consensus document on catheter and surgical ablation of atrial fibrillation.
Prolonged QTc significantly increases the risk of stroke
Elsayed Soliman, Winston-Salem, USA, and colleagues have found that prolonged QTc is associated with a significantly increased risk of stroke, indicating that drugs that prolong QTc may need to be investigated for a potential association with stroke.
St Jude Medical disputes study’s findings on Riata and Riata ST...
The medical device manufacturer St Jude Medical has called for the Heart Rhythm Journal to retract an online study in which the company's recalled Riata and Riata ST implantable cardioverter defibrillator (ICD) leads were associated with 71 deaths and Medtronic's Quattro Secure lead was associated with 62 deaths.
GLORIA-AF registry to explore use of antithrombotic therapy in 56,000 patients...
The registry programme will collect important data on the safety and comparative effectiveness of antithrombotic treatments, including vitamin K antagonist warfarin, acetylsalicylic acid and novel oral anticoagulants, such as dabigatran etexilate.
CircuLite provides updated clinical data on Synergy miniature ventricular support system...
Positive clinical data support Synergy's potential to improve haemodynamics, exercise capacity and quality of life in INTERMACS 4, 5, and 6 patients with chronic heart failure.
Ellipse ICD gets CE mark approval
The Ellipse (St Jude Medical) ICD's design was conceptualised by more than 200 physicians during focus groups in which they crafted in clay their vision for the ideal device design.
Medtronic Foundation launches online “Save-a-Life Simulator” to promote bystander response for...
The Medtronic Foundation's HeartRescue Project has produced an interactive, online experience, the "Save-a-Life Simulator," to promote proper and timely bystander response to sudden cardiac arrest (SCA).
Boston Scientific launches Ingenio and Advantio family of pacemakers in Europe
The Ingenio and Advantio pacemakers feature RightRate pacing technology designed to treat chronotropic incompetence.
Medtronic receives FDA approval to treat mildly symptomatic heart failure patients...
The FDA's decision was supported with data from the pivotal REVERSE and landmark RAFT clinical trials, which showed that CRT-D can benefit mildly symptomatic heart failure patients by reducing mortality and heart failure hospitalisation rates.
First landmark CIED replacement study of all companies’ cardiac devices provides...
The REPLACE study is the first prospective, multicentre trial to examine a broad range of complications related to replacement of all companies' cardiovascular implantable electronic devices (CIED) which includes both pacemakers and ICDs (implantable cardiac defibrillators).
RECORD study shows efficacy and safety for Biotronik Closed Loop Stimulation...
The RECORD investigation of CLS pacemakers is the largest to date and demonstrates excellent performance in all pacing sites within the right ventricle (apical, septal, outflow tract), and even in advanced heart failure with no difference to patients without heart failure.
DigiFab launched in the UK
DigiFab (BTG) is indicated for the treatment of patients with known (or strongly suspected) life-threatening digoxin toxicity associated with ventricular arrhythmias or bradyarrhythmias.
UK’s NICE recommends second new anticoagulant for atrial fibrillation
Following its recent recommendation for dabigatran (Pradaxa, Boehringer Ingelheim), the UK's National Institute for Health and Clinical Excellence (NICE) now recommends rivaroxaban (Xarelto, Bayer) as an option for preventing stroke and systemtic embolism in patients with non-valvular atrial fibrillation.
Pacemaker reduces syncope recurrence in patients with neurally mediated syncope
Results from the ISSUE 3 study show that active pacemaker therapy can reduce episodes of syncope in selected patients with severe asystolic neurally mediated syncope. Data were presented by Michele Brignole at the American College of Cardiology conference.
Invasive strategy improves survival in patients with myotonic dystrophy and conduction...
A study published in the Journal of the American Medical Association has found that an invasive strategy of systematic electrophysiology study and prophylactic pacemaker implantation in patients with myotonic dystrophy type one and major infranodal conduction delays was associated with a higher rate of nine-year survival than a non-invasive strategy.
Canadian Cardiovascular Society advocate using new anticoagulants instead of warfarin
If oral anticoagulation therapy is indicated in patients with atrial fibrillation, most patients should receive one of the three new anticoagulants ─ dabigatran, apixaban or rivaroxaban ─ (once approved) rather than warfarin, according to guidelines published in the Canadian Journal of Cardiology.
New FDA guidance on considerations used in device approval, de novo...
The guidance outlines clinical data, risks, benefits and patient risk tolerance.
“The Convergent Procedure may improve heart function and provide a viable...
In a study presented by Janez Toplisek, at ACC 2012, 85% of patients who underwent ablation with the multidisciplinary Convergent Procedure were in sinus rhythm at one year follow-up, had a significant reduction in left atrial size and improvement in left ventricular ejection fraction.
First wireless smartphone ECG shows success in monitoring heart health
The AliveCor smartphone ECG is an innovative, investigational medical wireless device which incorporates electrodes into a wireless case that snaps onto the back of a smart phone, allowing for wireless single-lead recording of 30-second rhythm strips that are stored securely in the cloud and the device itself.
St Jude Medical appoints Population Health Research Institute to validate and...
PHRI will review data from three combined registries on the Riata ST Optim and Durata implantable cardioverter defibrillator (ICD) leads.
HeartLight Endoscopic Ablation System now available in the Netherlands
Physicians at Isala Klinieken in Zwolle, Netherlands, were the first in the country to incorporate CardioFocus' visually guided ablation technology.
St Jude launches Accent MRI pacemaker in Australia
The new pacemaker and lead allow patients to undergo full-body, high-resolution magnetic resonance imaging (MRI) scans.
Targeted left ventricular lead placement significantly improves response rate
Results from the TARGET study have shown that using speckle-tracking echocardiography to target left ventricular lead placement for cardiac resynchronisation therapy (CRT) significantly improves the rate of response and clinical status compared with conventional therapy.
Novel anticoagulants have greater net benefit than warfarin in “real world”...
Amitava Banerjee, Birmingham, UK, and co-authors have used "real world" data to show that three new oral anticoagulants have greater net clinical benefit than warfarin in patients with atrial fibrillation who have a high risk of stroke and bleeding.
Use of an automated safety surveillance tool could have identified Fidelis...
A study, published ahead of print in Circulation Cardiovascular Quality Outcomes, shows that the Data Extraction and Longitudinal Trend Analysis (DELTA, Coping Systems) system could have triggered a sustained safety alert about the Sprint Fidelis lead (Medtronic) two years before the product was taken off the market.
Philips introduces enhanced HeartStart MRx Monitor/Defibrillator
The latest innovations of the HeartStart MRx are based on extensive feedback from emergency medical services professionals.
Computer software monitoring detects ICD malfunctions sooner
A software monitoring program that tracks implantable cardioverter-defibrillator (ICD) function could detect devices' malfunctions earlier than current monitoring processes, according to new research published in Circulation: Cardiovascular Quality and Outcomes.
Boston Scientific to Acquire Cameron Health
Cameron Health is the developer of the world's first and only commercially available subcutaneous implantable cardioverter defibrillator - the S-ICD system.
CapSure Sense MRI SureScan pacing leads get CE mark approval
The CapSure Sense MRI SureScan pacing leads (Medtronic) will give physicians an additional option that is MR-conditional, or designed to be safe for the MRI environment when used per specified MR conditions.
First peer-reviewed ICD implantation video is published in JoVE
The first peer-reviewed video demonstrating an implantable cardioverter-defibrillator (ICD) implantation has been published in JoVE, the Journal of Visualized Experiments.
FDA extends action date for apixaban’s new drug application by three...
Bristol-Myers Squibb and Pfizer have announced that the US Food and Drug Administration (FDA) has extended the action date by three months for the new drug application for apixaban (Eliquis) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Sodium channel blocker test has poor prognostic value in asymptomatic patients...
A study published online in the HeartRhythm Journal indicates that while the sodium channel blocker test has good prognostic value in symptomatic patients with non-diagnostic Brugada ECG (Br-ECG), it appears to have little value in asymptomatic patients.
Family trees could predict risk of death in inherited arrhythmias
Eline Nannenberg, Amsterdam, The Netherlands, and colleagues have found that the Family Tree Mortality Ratio (FTMR) method can identify the age ranges that carry the greatest risk of death from an inherited arrhythmia syndrome.
New study to investigate the role of early radiofrequency ablation in...
ATTEST, a prospective, multicentre, randomised, controlled study will compare pulmonary vein isolation (using Biosense Webster's ThermoCool catheters and the company's Carto 3 or Carto XP mapping systems) with drug therapy (rate or rhythm control) in patients with paroxysmal atrial fibrillation.
Atrial fibrillation is independently associated with cognitive and functional decline
According to a study published in the February issue of the Canadian Medical Association Journal, cognitive and functional decline are "important consequences" of atrial fibrillation even in the absence of overt stroke.
Steris announces collaborative alliance with St Jude Medical for advanced...
These labs feature technologies across the cardiovascular service line for hospitals and clinics interested in developing state-of-the-art laboratories that meet their changing clinical needs.
Preclinical study examines percutaneous approach to epicardial ablation of ventricular tachycardia
A new preclinical study shows that a unique minimally invasive percutaneous approach to accessing the heart may enable electrophysiologists to perform epicardial ablation for ventricular tachycardia.
First Teligen ICDs implanted in China
The Teligen implantable cardioverter defibrillators (Boston Scientific), designed to treat sudden cardiac death, are the smallest high-energy devices available in China.
Philips launches HeartStart XL+ defibrillator/monitor
The HeartStart XL+ is the only Philips defibrillator that, in AED mode, can defibrillate any patient - adult or child - with no special pads required.
First patient treated in CardioFocus HeartLight EAS US pivotal trial
The HeartLight EAS US pivotal trial is designed to evaluate the safety and efficacy of the HeartLight Endoscopic Ablation System (EAS) (CardioFocus) in treating symptomatic atrial fibrillation by creating electrical isolation of the pulmonary veins.
Scottish Medicines Consortium accepts rivaroxaban for NHS use in two new...
The anticoagulant rivaroxaban (Bayer HealthCare, Xarelto) has been accepted for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation who have one or more risk factors and for the treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism, following an acute DVT in adults.
Roche’s xCELLigence Cardio Instrument used to detect beating rhythm and proarrhythmic...
The xCELLigence Cardio Instrument is an impedance sensing instrument capable of reading signals at high sampling rates, making it possible to measure the contraction movements of cardiomyocytes in contact with sensor microelectrodes.
EP Europace journal widens its focus
EP Europace becomes the official journal to the European Heart Rhythm Association (EHRA), the European Society of Cardiology (ESC) Working Group (WG) on Cardiac Cellular Electrophysiology, and the ESC Working Group on e-Cardiology. It will additionally invite articles on research topics into the application of computing technology and data processing for electrophysiology.
Vdrive robotic navigation system gets Canada market clearance
The Vdrive system (Stereotaxis) allows physicians to remotely manipulate traditionally non-robotic catheters.
Call for new approach to ICD replacement
In an editorial in the New England Medical Journal, three leading specialists in the management of cardiac rhythm disorders argue for a more "considered and nuanced" approach to replacing implantable cardioverter defibrillators (ICD).
St Jude Medical launches new version of its remote patient monitoring...
The version 5.0 of the Merlin.net Patient Care Network includes a Mobile DirectAlerts notification feature for important patient and device alerts. This is a secure physician notification system compatible with iPhone, Android, iPad and Blackberry.
ROCKET-AF sub-analysis results presented at International Stroke Conference
A sub-analysis of data from the ROCKET-AF trial presented at the American Stroke Association's International Stroke Conference 2012 shows that rivaroxaban (Xarelto, Bayer Healthcare) might be better at preventing clot-related strokes in patients with atrial fibrillation while minimising the risk of causing a bleeding stroke.
Paroxysmal atrial fibrillation may account for some unexplained strokes
Occasional erratic heart rhythms appear to cause about one-fifth of strokes for which a cause is not readily established, according to research presented at the American Stroke Association's International Stroke Conference 2012.
FDA approves DF4 high-voltage connector system for ICDs and CRT-Ds
The DF4 (Medtronic) is a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
TomTec introduces 2D Cardiac Performance Analysis MR software solution for cardiac...
2D Cardiac Performance Analysis MR analyses myocardial function and deformation in standard magnetic resonance cine sequences and does not require specific acquisition modes like tagged imaging.
Middle-aged men with upper-normal blood pressure at risk for atrial fibrillation
Middle-aged men at the upper end of normal blood pressure had an elevated risk for atrial fibrillation later in life, according to new research published in Hypertension: Journal of the American Heart Association.
University of Michigan and Integrated Sensing Systems awarded US$1.5 million for...
The US National Institutes of Health 2.5-year grant will help test a miniature, battery-free, wireless device that will reduce the need for invasive cardiac catheterisation procedures and provide a better understanding of congenital heart disease in infants and children.
Biotronik successfully completes testing to connect Biotronik Home Monitoring to electronic...
Biotronik announced it has successfully completed its final interoperability testing process to connect Biotronik Home Monitoring to electronic health record systems through the Biotronik EHR DataSync technology.
Two poster presentations at Boston AF highlight positive results of a...
At Boston AF, two poster presentations showed that a multidisciplinary procedure that uses both epicardial and endocardial ablation (convergent procedure) is associated with high single procedure efficacy in a patient population dominated by persistent atrial fibrillation.
Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation, increase the risk of...
A new study, published in the New England Journal of Medicine, has added weight to the view that subclinical atrial fibrillation is a possible cause of cryptogenic stroke after finding that 13% of strokes and systemic embolisms in the study population were associated with subclinical atrial tachyarrhythmias.
Dronedarone’s story “not really over by any stretch”
At Boston AF, Peter Kowey, Pennsylvania, USA, declared that the recent failure of the PALLAS study did not mean that they were "throwing in the towel" with dronedarone and announced plans for a new dronedarone study.
New consensus document for atrial fibrillation ablation previewed at Boston AF
Hugh Calkins, Maryland, USA gave a sneak preview of the forthcoming 2012 document on catheter ablation for atrial fibrillation. At Boston AF he said, the new document is not just a "brief update" of the previous HRS/EHRA/ECAS document, which was published in 2007, but a "comprehensive, state-of-the-art review of the field of catheter and surgical ablation for atrial fibrillation."
Angelo Auricchio
Angelo Auricchio, president of the European Heart Rhythm Association, reviews the highlights of his impressive career with Cardiac Rhythm News.
First patient enrolled in Fire and Ice clinical trial
Fire and Ice is a prospective, randomised, multinational head-to-head clinical trial comparing the long-term safety, effectiveness and ease of use of the Medtronic Arctic Front cardiac cryoablation system compared to the Biosense Webster Carto system guided Thermocool catheter to treat patients with symptomatic paroxysmal atrial fibrillation.
Hartford Hospital Selected as a “centre of excellence” for Sensei X...
This new centre of excellence, selected by Hansen Medical, will serve as the training centre for the Northern United States and is expected to commence operation in February 2012.
Antithrombotic drug market will rise to US$24.4 billion in 2015
A new report by visiongain predicts that the overall world antithrombotic and anticoagulant drug market will reach US$24.4 billion in 2015.
Single atrial fibrillation ablation procedure achieves high pulmonary vein isolation rates,...
Researchers in Germany achieve 98% acute pulmonary vein isolation, with 77% of patients in sinus rhythm at approximately nine months follow-up.
Terumo to distribute TigerPaw system II, left atrial appendage closure device,...
The TigerPaw system II (LAAx) is indicated for occlusion of the left atrial appendage under direct visualisation, in conjunction with other open cardiac procedures.
Pan-European stroke prevention in atrial fibrillation registry PREFER in AF enrols...
The registry will gather information from valvular and non-valvular atrial fibrillation patients. It will also track the impact of new anticoagulant therapies on stroke prevention, in addition to collating insights into patients' satisfaction with their entire atrial fibrillation management and the overall health economic burden of atrial fibrillation across Europe.
St Jude launches Accent MRI pacemaker in India
The new pacemaker and lead allow patients to undergo full-body, high-resolution magnetic resonance imaging (MRI) scans.
Data from ASSERT implantable device monitoring study published in New England...
Study illustrates the effectiveness of detecting patients with higher risk of stroke using implantable device monitoring.
FDA approves Thermocool SF catheter
The Thermocool SF irrigated ablation catheter (Biosense Webster) has been approved for treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with Carto systems and type 1 atrial flutter for patients 18 years and older.
Revised ablation guidelines previewed at Boston AF
Preview of the revised HRS/EHRA/ECAS consensus document on catheter ablation for atrial fibrillation at Boston AF (12-14 January 2012, Boston, USA) reveals new recommendation to use the CHADS2-VASc score
Trial reviews and live case presentations at Boston AF
The first day of Boston AF (12 January 2012, Boston, Massachusetts, USA) was a mixture of best paper reviews and live case presentations.
SMART-AF trial completes patient enrolment
The SMART-AF clinical study is designed to demonstrate the safety and effectiveness of the Thermocool Smarttouch catheter (Biosense Webster) in the treatment of symptomatic, drug-refractory, paroxysmal atrial fibrillation.
Endosense launches TactiCath 75 force-sensing catheter, announces new results of EFFICAS...
The TactiCath 75 is an 8.5 F sheath compatible, state-of-the-art open irrigated, steerable radiofrequency ablation catheter that employs the same proprietary force-sensing technology as the original TactiCath but features a longer, 75 millimeter curved tip.
Sensei X robotic catheter system to be presented at Boston AF
The Sensei X robotic catheter system (Hansel Medical) is a flexible robotic platform that integrates advanced catheter control with 3D visualisation, designed to provide catheter stability with force sensing, instinctive and precise catheter placement.
Experts unveil tools to improve atrial fibrillation care
Four interventions to enhance the care and treatment of individuals with atrial fibrillation were presented on 10 January 2011 at a press briefing hosted by The American College of Physicians Foundation's initiative on atrial fibrillation and stroke prevention.
Biosense Webster and GE Healthcare sign co-distribution agreement in the USA
Under the terms of the agreement, Biosense Webster will offer a suite of GE electrophysiology systems, including CardioLab EP recording system, and GE will distribute Biosense Webster's navigation system, the Carto 3 system.
Catharina Hospital and Philips start social media initiative with heart patient
A catheter ablation treatment of a patient with a heart rhythm disorder could be followed via social media, before, during and after the procedure. The initiative is lead by Catharina Hospital in The Netherlands and Philips.
Niobe ES magnetic navigation system shows positive results for cardiac arrhythmias...
Positive initial results with the Niobe ES system (Stereotaxis) in Europe demonstrate that the average time for completion of mapping and ablation for the atrial fibrillation patients was 69 minutes.
Genetic sudden cardiac death screening test on the horizon
The Montreal Heart Institute will work with GnuBIO to develop a genetic sudden cardiac death screening panel in order to predict risk in patients.
Cameron Health submits PMA application to FDA for the S-ICD system
The premarket application (PMA) submission included data from a 330-patient pivotal IDE clinical study which evaluated the safety and efficacy of the S-ICD system in patients at risk of sudden cardiac death.
Dabigatran associated with increased risk of acute coronary events
The anticoagulant dabigatran (Boehringer Ingelheim's Pradaxa) is associated with an increased risk of myocardial infarction or acute coronary syndrome in a broad spectrum of patients when tested against some other medicines, according to a study published online by the Archives of Internal Medicine.
NICE needs more evidence on rivaroxaban for prevention of stroke in...
In preliminary recommendations published on 9 January, NICE is asking Bayer HealthCare for more information on its product rivaroxaban (Xarelto), for the prevention of stroke and systemic embolism in people with atrial fibrillation.
Rhythmview system featured at Boston Atrial Fibrillation Symposium 2012
Rhythmview (Topera Medical) is a mapping system that helps identify the electrical source of cardiac arrhythmias. It will be utilised as part of a complex procedure demonstration on 12 January at the 17th Annual Boston Atrial Fibrillation Symposium.
Gene analysis helps identify basis of rare infant heart disorder
Researchers from USA have found differences in gene expression that could indicate a predisposition for histiocytoid cardiomyopathy (HC) in infants.
AirStrip Technologies receives CE mark for mobile patient monitoring solutions
The applications which include AirStrip OB, AirStrip Cardiology and AirStrip Patient Monitoring give clinicians anytime, anywhere access to vital live and historical patient data including waveforms, ECGs and other information, right on their smartphone or tablet.
St Jude Medical launches Riata Communication website
New website is dedicated to updating the physician community on Riata silicone lead information.
Magnetecs receives CE mark for Catheter Guidence Control and Imaging system
The Catheter Guidance Control and Imaging system allows robotic guidance, control and imaging of catheters and other advanced tools used in electrophysiological and other procedures.
Nerve surgery may help to suppress ventricular arrhythmias
Cardiologists from the University of California, Los Angeles (UCLA) have found that surgery to snip nerves related to the sympathetic nervous system on both the left and right sides of the chest, may be helpful in stopping electrical storms when other treatment methods have failed.
FDA adds new warnings to dronedarone
Dronedarone (Multaq, Sanofi Aventis) should not be prescribed to patients with atrial fibrillation who cannot or will not be converted into normal sinus rhythm, FDA advises.
FDA approves AtriCure’s Synergy Ablation system for atrial fibrillation treatment
AtriCure's Synergy Ablation system has been approved for the treatment of patients with persistent and long-standing persistent atrial fibrillation during open-heart concomitant coronary artery bypass grafting and/or valve replacement or repair procedures.
Cardiac resyncronisation therapy reduces rates of death and re-hospitalisation in heart...
The survey a joint initiative of the Heart Failure Association and European Heart Rhythm Association of the European Society of Cardiology (ESC) gathered information on more than 2000 patients at 141 centres in 13 European countries.
Rivaroxaban approved in the UK for two new indications
Rivaroxaban (Xarelto, Bayer Healthcare) has been approved in the UK for the prevention of non-valvular AF-related stroke and systemic embolism and treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism following an acute DVT in adults.
Stereotaxis initiates shipments of the Epoch electrophysiology platform
Initial shipments include system upgrades to the new generation Epoch platform from the Niobe II navigation system for customers in the USA and Europe.
The future of remote monitoring
Stefan Sack, Munich, Germany speaks to Cardiac Rhythm News about what current data for remote monitoring shows and what studies on remote monitoring are currently investigating.
The risk of atrial fibrillation with COX-2 inhibitors may have been...
A new study in the European Heart Journal indicates that while restrictions on the use of cycloocygenase (COX)-2 inhibitors may have limited the feared cardiovascular consequences of the drugs, the risk of atrial fibrillation may have been overlooked and may warrant further consideration.
1000th patient implanted with world’s only completely subcutaneous implantable defibrillator
Lara Dabiri Abkenari, in association with Luc Jordaens at the Erasmus Medical Center in Rotterdam, The Netherlands implanted the 1000th patient with the S-ICD system (Cameron Health).
Estech starts patient enrolment in HISTORIC-AF European ablation study
The HISTORIC-AF staged hybrid ablation study will enrol persistent and long-standing persistent atrial fibrillation (AF) patients at ten centres in Italy, Germany, the United Kingdom, France, and Poland.
Remote monitoring as safe as standard follow-up in pacemakers
A new study in the European Heart Journal shows that Biotronik's Home Monitoring system is as safe as standard follow-up in patients with pacemakers.
The FDA is to investigate dabigatran after reports of severe bleeding
Following post-market reports of severe bleeding with dabigatran (Pradaxa, Boehringer Ingelheim), the FDA is to investigate whether the reports show that severe bleeding is more frequent than would be expected given the results of the RE-LY study.
FDA Advisory Panel recommends against approval of Champion heart failure management...
While the panel agreed that the CardioMEMS technology is safe with a vote of 9-1, the majority did not vote positively that the system is effective and that reasonable assurance of the risks associated with the device outweigh the potential clinical benefits of the technology.
Speckle tracking echocardiography competes with MRI for infarct size quantification
"The advantages of speckle tracking echocardiography (STE) over magnetic resonance imaging (MRI) is that it is far quicker to use, cheaper, and can be used by cardiologists at the bedside with portable machines, and repeated serially when ever needed," said Luigi Badano, University of Padua, Italy.
FDA Advisory Panel recommends expanded indication for Medtronic cardiac resynchronisation therapy...
FDA's Circulatory Systems Devices Advisory Panel determined that the overall clinical benefits of Medtronic cardiac resynchronisation therapy with implantable cardioverter defibrillator (CRT-D) devices outweigh the risks in treating certain mildly symptomatic heart failure patients.
Virginia Cardiovascular Associates and Angel Medical Systems announce ALERTS pivotal study...
ALERTS will evaluate the safety and effectiveness of the AngelMed Guardian implantable cardiac monitor and alert system, designed to reduce patient time to the emergency room and improve survival rates from heart attack in high-risk patients.
Roche, ChanTest collaborate for preclinical cardiac safety testing of drug compounds...
Testing on iCell Cardiomyocytes can help researchers detect potential cardiac safety issues with drug candidates early in the discovery process before in-vivo animal or human testing is conducted.
MedSolutions launches programme to reduce unnecessary ICD surgeries
MedSolutions, a leading provider of quality-driven medical cost management services, announced the launch of its Implantable Cardioverter Defibrillator (ICD) Surgery Management Program, which uses evidence-based guidelines to ensure the clinical appropriateness of ICD and cardiac resynchronization therapy defibrillator (CRT-D) implantation.MedSolutions, a leading provider of quality-driven medical cost management services, announced the launch of its Implantable Cardioverter Defibrillator (ICD)
More work needed to reduce strokes due to atrial fibrillation in...
A study published in BMJ Open has found that although the number of strokes has fallen in the UK, more needs to be done to reduce the risk of stroke in patients with atrial fibrillation. Additionally, it seems that while the use of anticoagulants does not increase with increasing CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score in patients with atrial fibrillation, the use of antiplatelets does increase
What do we know about vernakalant?
At Europe AF, 21-22nd November, London, UK, John Camm (professor of clinical cardiology, St George's University, London, UK) reviewed the available data for vernakalant (Brinavess; MSD, Cardiome Pharma)
Back to the drawing board as ALPHEE study fails to show...
A study presented at the recent 2011 AHA sessions and published online in Circulation has found that the new antiarrhythmic drug celivarone does not prevent implantable cardioverter defibrillator (ICDs) interventions or sudden cardiac death, ending hopes that the drug would be a new weapon in the antiarrhythmic drugs armoury.
Surgical ablation is more effective but has more procedure-related adverse events...
A trial, simultaneously published online in Circulation and presented at the annual scientific sessions of the American Heart Association (AHA; 12-16 November, Orlando, Florida) has found that minimally invasive surgical ablation is more effective than catheter ablation but is also associated with more procedure-related adverse events
Biotronik introduces the world’s first and only implantable defibrillators eligible for...
Biotronik announced the first implantations of the new Lumax 740 implantable cardiac defibrillators in European countries. According to the company, this is the world's first and only ICDs eligible for use with magnetic resonance imaging.
Philips launches HeartStart FR3 automated external defibrillator for sudden cardiac arrest...
According to the company, the HeartStart FR3 significantly reduces deployment time by eliminating steps to help responders start delivery of the right therapy-cardiopulmonary or defibrillation- on the patient faster.
FDA grants IDE approval to CorMatrix for extracellular matrix study for...
The study aims to demonstrate the safety and efficacy of the CorMatrix extracellular matrix (ECM) for pericadial closure to reduce the incidence of new onset postoperative atrial fibrillation following isolated primary coronary artery bypass graft (CABG) surgery.
Watchman device implanted in first patients in Latin America
The Watchman device (Boston Scientific) is designed for use in patients with atrial fibrillation who are at risk for stroke and are eligible for long-term oral anticoagulation therapy such as warfarin. The device is designed to close the left atrial appendage therefore could be used as an alternative to long-term anticoagulation therapy.
LifeVest wearable defibrillator reduces total mortality after cardiac revascularisation, study shows
Survival curves showed an 80% reduction in total mortality at 90 days for LifeVest patients as compared to non LifeVest patients post percutaneous coronary intervention, with 90 day mortality of 2% for LifeVest patients versus 10% for non-LifeVest patients.
Boston Scientific begins marketing remote catheter system in Europe through exclusive...
The CRI Amigo system, compatible with certain Boston Scientific and other commercially available catheters, lets physicians remotely maneuver diagnostic and ablation catheters designed to treat common cardiac arrhythmias during electrophysiology procedures.
Rivaroxaban added to standard antiplatelet therapy significantly reduces secondary cardiovascular events...
Results from the ATLAS ACS 2 TIMI 51 study showed that both 2.5 or 5 mg of rivaroxaban dosed twice daily in addition to standard therapy was superior to standard therapy alone in the primary efficacy endpoint of preventing cardiovascular death, myocardial infarction or stroke in patients with acute coronary syndrome.
New RE-LY sub-analyses demonstrate safety and efficacy of Pradaxa in patients...
Pradaxa (dabigatran etexilate) 150mg bid reduced the risk of stroke in atrial fibrillation patients with symptomatic heart failure and non-valvular atrial fibrillation compared to well-controlled warfarin.
NICE recommends dabigatran for prevention of stroke in AF patients
In a final draft guidance published on 1 November the UK National Institute for Health and Clinical Excellence (NICE) has recommended dabigatran (Pradaxa, Boehringer Ingelheim), in accordance with its licensed indications, for the prevention of stroke and systemic embolism in people with atrial fibrillation.
Measuring both left atrial size and the amount of left atrial...
A study, published in Heart, indicates that the combined assessment of left atrial size and the amount of left atrial fibrosis may improve the identification of patients who have a high likelihood of successful ablation.
MRI may be safe in selected patients with cardiac rhythm management...
A study published in the Annals of Internal Medicine, the largest published experience of MRI in standard, contemporary cardiac rhythm management devices (CRMDs) to date, shows that MRI can be done safely, with appropriate precautions, in patients with selected cardiac devices.
FDA approves rivaroxaban to prevent stroke in non-valvular atrial fibrillation patients
The Food and Drug Administration's approval is largely based on the results from the ROCKET-AF trial, a double-blind global phase III study that showed the safety and efficacy of rivaroxaban (Xarelto, Bayer Healthcare).
New economic model shows that remote monitoring reduces hospital workload and...
Biotronik presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Madrid, Spain, information highlighting the healthcare burden of following-up pacemaker, implantable cardioverter-defibrillator (ICD) and cardiac resynchronisation therapy (CRT) patients in Germany and the UK.
First patient enrolled in the ISIS-ICD clinical study
The primary objective of the study is to evaluate the percentage of patients implanted with an implantable cardioverter-defibrillator (ICD), featuring the Sorin PARAD discrimination algorithm, that are free from inappropriate ICD shocks over a one-year follow-up.
FDA advisory panel votes against Medtronic Phased RF Ablation System for...
The majority of the panel does not believe there is reasonable assurance of the safety of Medtronic's ablation system, and that the clinical benefits of the technology do not outweigh the potential risks based on the TTOP-AF clinical trial data.
Surgical ablation system for atrial fibrillation receives recommendation from FDA expert...
FDA's Circulatory System Devices Panel recommended AtriCure's Synergy ablation system for the treatment of atrial fibrillation during open-heart concomitant surgical procedures.
Obesity- and alcohol-related cardiomyopathies are common causes of nonischaemic sudden cardiac...
A study of a Finish population, published online in Heart Rhythm, indicates that cardiomyopathy associated with obesity, alcoholic cardiomyopathy, and fibrotic cardiomyopathy are common causes of nonischaemic sudden cardiac death.
Developing a business case for the left atrial appendage occlusion device
Tim Betts, UK, outlined a business case, at the Heart Rhythm congress (2-5 October 2011, Birmingham, UK) to put to commissioners, for using the percutaneous left atrial appendage (LAA) occlusion device (Watchman, Boston Scientific) for stroke prevention in patients with atrial fibrillation.
Warfarin “swingers” are good candidates for novel anticoagulants
Warfarin "swingers"-patients who frequently fall outside of the therapeutic range (international normalised ratio, INR, 2-3) for optimum warfarin control-are a group likely to benefit from being switched from warfarin to a novel oral anticoagulant, according to Ian Menown, Cardiologist, Craigavon Cardiac Centre, Northern Ireland.
Hansen Medical initiates clinical trial evaluating Sensei X robotic system for...
The Early robotic ablation by substrate elimination of ventricular tachycardia study (ERASE-VT), is planned to enrol 200 patients with implantable cardioverter defibrillators (ICDs) at up to eight sites in Europe.
The impact of the STOP-VT study
Rainer Moosdorf, Germany, reviews the impact of the STOP VT trial. As reported in the 14th issue of Cardiac Rhythm News, this multicentre study showed that remote magnetic navigation may provide additional benefits to catheter ablation for the treatment of scar-related ventricular tachycardia.
Atrial fibrillation undertreated as one of the major risk factors for...
Despite significant improvements in stroke prevention over the past decade, and a fall in incidence and deaths, UK doctors are still undertreating one of the major risk factors-atrial fibrillation-reveals research published in BMJ Open.
Study supports use of Cambridge Heart’s MTWA test as predictor of...
At a median follow-up time of 36 months, patients with an abnormal Microvolt T-Wave Alternans (MTWA) test were 4.4 times more likely to experience a life-threatening arrhythmia or sudden cardiac death than those with a normal test and were almost eight times more likely to die of cardiac causes, according to results from the PREVENT-SCD trial.
Persistent AF patient treated with HeartLight in live case at Venice...
Further research presented during the scientific sessions showed that the CardioFocus' balloon system achieved 99% acute pulmonary vein isolation irrespective of vein anatomy.
SORIN’s SonR CRT device gets CE mark
SonR is the first and only system to provide weekly automatic optimisation during patient's real life activities as an alternative to in-clinic manual echocardiography-based device optimisation for improved cardiac resyncronisation therapy response.
Ablation therapy in atrial fibrillation patients shows to be effective but...
The TTOP-AF trial results showed a 90% reduction in atrial fibrillation or atrial flutter burden in 55.8% of ablation patients; however the results did not meet the pre"defined performance safety goal of 16%.
St. Jude Medical adds mobile notifications to its remote patient monitoring...
The new additions provide physicians easier access to important alerts and improve efficiency of data transmission to electronic health records.
CardioFocus HeartLight EAS to be presented at Venice Arrhytmias 2011
The endoscopic ablation system which is used for pulmonary vein isolation in the treatment of atrial fibrillation, will be highlighted in a "live case" session performed by Sakis Themistoclakis and Andrea Natale
Andrea Natale
Andrea Natale, co-president of Venice Arrhythmias (9-12 October 2011), is one of the pioneers in ablation of atrial fibrillation, he spoke to Cardiac Rhythm News about this as one of his proudest moments, he also told who inspired him into electrophysiology and what is expected for Venice Arrythmias 2011.
Should we have preparticipation ECG screening in young athletes?
Will Nicolson, University of Leicester, UK, comments on the findings from the two new studies on electrocardiograms for preparticipation screening in young athletes published in the Journal of Pediatrics and Circulation. He said that according to the results "it is possible that preparticipation ECG screening would cause more long-term deaths through inactivity than it saved through appropriate diagnosis in the short term."
New study suggests that electrocardiograms may not be the right tool...
There is ongoing debate as to whether or not young athletes should undergo preparticipation screening, using an electrocardiogram (ECG), to reduce the risk of sudden cardiac death. A new study indicates that preparticipation ECGs are difficult to interpret and as a result, the wrong guidance may be given.
Gender does not affect periprocedural complications or long-term results of catheter...
Despite influencing the epidemiology, pathology, and clinical presentation of cardiac arrhythmias, gender does not appear to affect periprocedural complications and outcomes of catheter ablation, according to a study presented by Sonia Ammar, Munich, Germany at EHRA-Europace in Madrid, Spain.
Quick View report: new addition to Biotronik Home Monitoring
The Quick View report is designed to improve the speed at which clinicians can find and review patient device (pacemaker or implantable cardioverter-defribrillator) data by providing a very intuitive, user-friendly presentation of the information.
Heartbeat International launches One Heart Magazine on World Heart Day
One Heart Magazine, the voice of the Global Cardiovascular Alliance, will highlight corporations, nonprofit organisations, individuals, and strategic alliances that are working to further the cause of this charitable foundation dedicated to provide cardiovascular implantable devices and treatment to people in need around the world.
Biotronik launches next-generation programmer for implantable cardiac devices in Japan
Remanic provides an optimised user interface to increase patient's follow-up efficiency as well as a retractable and adjustable touchscreen for optimised viewing and handling.
European Medicines Agency recommends restricting use of Multaq
According to the Agency, the anti-arrhythmic medicine should only be prescribed for maintaining heart rhythm in patients with paroxysmal or persistent atrial fibrillation for the maintenance of sinus rhythm after successful cardioversion.
Jan Keltjens is the new president and CEO of Endosense
Keltjens has previously served as chief executive officer of AngioDynamics and CryoCath Technologies (now Medtronic CryoCath) and held a number of senior leadership positions at Cordis.
Costs, mortality increase following infection in cardiac device recipients
A new US study shows that infections associated with pacemakers and defibrillators led to 4.8 to 7.7-fold increases in admission mortality, 1.6 to 2.1-fold increases long term mortality, 2.5 to 4.0-fold increases in hospital length of stay, and 1.4 to 1.8-fold increases in cost compared to pacemaker and defibrillator implantations without infection.
St. Jude Medical launches quadripolar pacing system in India
The Promote Quadra CRT-D quadripolar pacing system offers physicians the ability to address pacing complications without the need to surgically reposition a lead.
Automated external defibrillators failures connected to deaths from cardiac arrest
More than 1,000 cardiac arrest deaths over 15 years are connected to the failure of automated external defibrillators (AEDs), according to a study published in Annals of Emergency Medicine.
St. Jude Medical initiates study to evaluate ST monitoring technology
The first patient has been enrolled in the Analyze ST clinical study to evaluate the effectiveness of an ST segment monitoring feature in St Jude's Fortify ST implantable cardioverter defibrillator (ICD) to detect acute coronary events.
FDA’s Advisory Committee recommends approval of rivaroxaban
The US Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban (Xarelto, Bayer) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
The latest results from the PACE study show that biventricular pacing...
The two-year results are consistent with the findings of the original PACE study: that biventricular pacing provides protection against the adverse effects of right ventricular apical pacing on systolic function and remodelling.
Remote magnetic navigation and ablation shows promise in patients with scar-related...
"The main advantage of the Niobe Remote Magnetic Navigation System (Stereotaxis), is the precise mapping and identification of the critical diseased portions of the heart that allows physicians to perform ablation in a more effective way," said Petr Neuzil, lead investigator of the STOP-VT study presented at the ESC Congress in Paris.
Two studies show that remote monitoring reduces inappropriate shocks
The ECOST and the EVATEL studies presented at the ESC Congress, Paris, France, show that remote monitoring (of cardiac rhythm management devices) reduces the number of inappropriate shocks compared with standard follow-up.
Novel anticoagulant apixaban reduces stroke and major bleeding compared with warfarin...
New data from the ARISTOTLE study showed that the rate of haemorrhagic stroke in the apixaban group was 49% lower and the rate of ischaemic stroke was 8% lower than in the warfarin group. Results were presented by Christopher Granger, USA, at the European Society of Cardiology (ESC) Congress (27-31 August 2011, Paris, France).
Enhanced pacemaker algorithm may potentially reduce the risk of adverse clinical...
The study has indicated that enhanced atrioventricular search hysteresis algorithm reduces unnecessary right ventricular pacing which correlates with less risk of heart failure hospitalisation, mortality and atrial fibrillation.
Selectra CRT lead delivery system gets CE mark
Selectra's unique handle design has an integrated side port, allowing for maximum flexibility and one-handed manipulation, which results in ultimate convenience during even the most challenging implantations.
ECOST trial demonstrates reduction of inappropriate shocks and improvement of battery...
ECOST is the first trial to show a 52% reduction of the number of patients with inappropriate shocks and a 72% reduction in the risk of hospitalisations related to inappropriate shocks.
New renal impairment data from ROCKET AF study of rivaroxaban shows...
"The findings of this analysis demonstrate that rivaroxaban has the ability to prevent stroke in patients with moderate renal insufficiency, without elevating the risk of critical bleeding events such as intra-cranial haemorrhage," said Keith Fox at the European Society of Cardiology Congress in Paris.
Biotronik’s cardiac Home Monitoring system contributes in earlier detection of cardiovascular...
Results from the Home-CARE (Home monitoring in cardiac resynchronisation therapy) clinical study showed that combining several physiological parameters into a single algorithm may help to improve the early detection of cardiovascular events.
Eliquis (apixaban) superior to warfarin for the reduction of stroke, major...
Eliquis (Bristol-Myers Squibb and Pfizer), compared to standard of care warfarin, significantly reduced risk of stroke or systemic embolism by 21%, risk of major bleeding by 31% and mortality by 11%.
Biotronik announces sponsored clinical trials at ESC 2011
Biotronik announced the list of its sponsored clinical studies on remote monitoring in ICD and CRT-D patients to be presented at the European Society of Cardiology (ESC) Congress to be held in Paris, France, from 27-31 August 2011.
HeartLight endoscopic ablation system available in the UK
HeartLight EAS (CardioFocus) is used for the treatment of atrial fibrillation. It features an illuminating endoscope to provide physicians with direct visualisation within a beating heart, in real time and without radiation.
EPi-Sense epicardial ablation system gets CE mark
The EPi-Sense (nContact) features first-of-its kind epicardial sensing electrodes designed to allow both electrophysiologists and cardiothoracic surgeons to map and navigate the epicardium and locate areas for linear epicardial ablation.
FDA provides clarification on benefit-risk determinations for medical devices guidelines
The recommendations made in the guidance are intended to improve the predictability, consistency and transparency of the premarket review process for applicable devices, and should help manufacturers navigate the approval process more easily.
FDA clears Centauri ambulatory cardiac diagnostic monitor
In response to the cardiac industry trend of shifting patient care from health-care settings to home, Centauri (IntriCon) gives physicians the flexibility to identify and monitor asymptomatic patient cardiac arrhythmias remotely.
Landmark pan-European atrial fibrillation trial recruits first patient
The EAST clinical trial is the largest pan-European study to evaluate whether an early and comprehensive rhythm control treatment of patients with early onset atrial fibrillation produces better patient outcomes than usual care alone.
Optical stimulation may offer a new way to control heart function
A new technique that stimulates heart muscle cells with low-energy light raises the possibility of future light-controlled, long-lasting pacemakers and defibrillators, the technique might also be used to test new drugs for possible cardiac side effects, study shows.
New study shows that cigarette smoking doubles the risk of atrial...
A large, multi-year, biracial study is first to show more than a two-fold increase of incident atrial fibrillation in current smokers compared to those who have never smoked.
Pradaxa (dabigatran etexilate) now licensed for use in the UK
The recommended dose, Pradaxa 150mg twice daily, is licensed in the United Kingdom for the prevention of stroke and systemic embolism in eligible adult patients with atrial fibrillation.
Novel nitinol guidewire associated with high success rate for transseptal punctures
A novel nitinol guidewire (SafeSept, Pressure Products) may be an alternative to transoesophageal or intracardiac echocardiogram for transseptal puncture for left atrium catheter ablation, study shows.
Heart rhythm charities launch patient surveys to gather information on arrhythmias...
Arrhythmia Alliance (A-A) and sister charity, Syncope Trust And Reflex Anoxic Seizures (STARS) surveys' results will be used to help inform, educate and raise awareness of heart rhythm disorders and syncope globally.
ROCKET-AF results published
ROCKET-AF co-chair Keith Fox, from the Centre for Cardiovascular Science at the University of Edinburgh, UK, talks to Cardiac Rhythm News about the study and its implications.
Rivaroxaban superior than warfarin, ROCKET AF study shows
Rivaroxaban (Xarelto, Bayer) successfully met the primary efficacy endpoint of non-inferiority in the prevention of stroke and non-central nervous system embolism in non-valvular atrial fibrillation, with superior efficacy demonstrated compared to warfarin whilst on active treatment.
ESC announces review on atrial fibrillation guidelines
Following the early termination of the PALLAS trial, the Guidelines Department of the European Society of Cardiology (ESC) has issued a new statement with regards to the use of dronedarone in atrial fibrillation patients, in accordance with advice given by the European Medicines Agency and the US Food and Drug Administration.
FDA gives IDE approval to Advisa DR MRI SureScan pacing system
Medtronic will conduct a prospective, randomised, controlled, non-blinded, multicentre clinical trial to confirm the safety and effectiveness of its second generation pacing system, in the clinical magnetic resonance imaging setting under specified conditions.
Postmenopausal women with existing cardiovascular conditions are at an increased risk...
Researchers from the University of Pennsylvania found that previous myocardial infarction, heart failure, atrial fibrillation, physical inactivity, diabetes, and reduced kidney function are all closely associated with sudden cardiac death.
FDA to seek public opinion on Institute of Medicine’s 510(K) recommendations
"FDA believes that the 510(k) process should not be eliminated but we are open to additional proposals and approaches for continued improvement of our device review programmes," said Jeffrey Shuren, director of the FDA's Center for Devices and Radiological Health.
First atrial flutter patient treated with novel MRI ablation catheter
The development of this novel catheter, specially designed to be used with magnetic resonance imaging, could represent a significant new opportunity for improved therapy of complex cardiac arrhythmias.
Institute of Medicine advices FDA to replace current 510(k) clearance process
The 510(k) process lacks the legal basis to be a reliable premarket screen of the safety and effectiveness of moderate-risk Class II devices and cannot be transformed into one, according to the US Institute of Medicine of the National Academies of Science.
Adrenaline shows positive results in cardiac arrest treatment
Spontaneous circulation was restored three times more commonly with adrenaline (23.5%) than with saline placebo (8.4%) after cardiac arrest treatment, according to a study to be published in the journal Resuscitation.
FDA releases draft guidance on device changes that require new 510(k)
Specific kinds of labeling changes, changes to the technology used in the device, changes in performance specifications, manufacturing changes, and changes in the materials used in the manufacture of the device are part of the clarifications included in the FDA's draft guidance.
New defibrillation method may lead to less pain
The new method, developed by Cornell University scientists, terminates the turbulent electrical activity within the heart. The weak electrical signals create "virtual electrodes" that stimulate heterogeneities within the heart and, particularly, the blood vessels.
CRT significantly improves LV dyssynchrony and contractile function
New data from the MADIT-CRT study shows that cardiac resynchronisation therapy with a defibrillator (CRT-D) significantly improves both left ventricular dyssynchrony and contractile function in patients with class I or II heart failure.
Double the number of deaths with dronedarone in permanent AF
The number of deaths in the dronedarone (Multaq, Sanofi Aventis) arm of the recently halted PALLAS study was double the number of deaths in the control arm, according to figures released by the US Food and Drug Administration (FDA).
Biosense Webster enrols first patient in the SMART-AF IDE study
The SMART-AF investigational device exemption study is designed to demonstrate the safety and effectiveness of ThermoCool SmartTouch and FDA approved NaviStar ThermoCool catheter family, in the treatment of symptomatic, drug-refractory, paroxysmal atrial fibrillation.
Endosense and Siemens complete first patient case utilising new contact-Âforce visualisation...
The new software is designed to give electrophysiologists access to contact-force information in a fluoroscopically enabled, three-dimensional anatomic heart model with X-ray based catheter tracking system.
European Medicines Agency reviews cardiovascular risk of Multaq
This follows Sanofi's announcement on 7 July 2011 of its discontinuation of the PALLAS study, because of the occurrence of severe cardiovascular events in some patients taking Multaq.
Sanofi stops phase IIIb of trial using dronedarone in patients with...
The decision follows recommendations from the PALLAS trial's Operations Committee and the Data Monitoring Committee (DMC) which observed a significant increase in cardiovascular events in the dronedarone arm.
Cell therapy for heart disease and arrhythmias: different cell different outcome
The take-home message from a session on the electrophysiological aspects in stem cell therapy at the recent EHRA-Europace Congress (Madrid, Spain) is that more research is needed to resolve the issue of the risk of arrhythmias with the use of stem cells in myocardial repair.
Camm: “The true incidence of sudden cardiac death in USA and...
John Camm, St Georges University of London, United Kingdom, overviewed the incidence of sudden cardiac death in Europe and USA at the European Heart Rhythm Association (EHRA)-Europace Congress in Madrid, Spain (26-29 June 2011)
Remote monitoring – the remote future of ICD?
The popularity of remote monitoring systems for implantable cardiac rhythm management devices is slowly increasing, according to Vidal Essebag, McGill University, Montreal, Canada.
Atrial fibrillation is emerging as the new epidemic
Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with AF remain unacceptably high, according to a joint report by the German Competence Network on Atrial Fibrillation (AFNET) and the European Heart Rhythm Association (EHRA).
Endosense and GE Healthcare sign joint development agreement to improve catheter...
The agreement will integrate the contact-force data provided by Endosense into GE's CardioLab electrophysiology recording and Innova imaging platforms.
Eliquis (apixaban) meets primary and key secondary endpoints in phase III...
In this study of patients with atrial fibrillation and at least one additional risk factor for stroke, Eliquis (Bristol-Myers and Pfizer) met the primary efficacy objective of non-inferiority to warfarin on the combined outcome of stroke.
Europe’s leading congresses in cardiac electrophysiology agree to develop a common...
Under the agreement, EHRA-Europace and Cardiostim share a wish to avoid fragmentation and create a common vision and objective - to promote the field of electrophysiology.
Medtronic introduces first mobile application for implantable cardiac devices
Medtronic announced the launch of Medtronic's first mobile application for use with implantable cardiac devices. With access to alert transmissions via the CareLink mobile application, health care providers can now manage their patients anytime and anywhere.
St. Jude Medical announces Japanese launch of smaller, higher Power ICD...
The reduced footprint of the Fortify ST implantable cardioverter defibrillator (ICD) and Unify cardiac resynchronisation therapy defibrillator (CRT-D) makes them the smallest available in the industry.
Bruce Wilkoff is the new HRS president
Meet the new Heart Rhythm Society's president 2011-2012: Bruce Wilkoff, director of Cardiac Pacing and Tachyarrhythmia Devices in the Department of Cardiovascular Medicine at the Cleveland Clinic.
Dutch experience deems totally subcutaneous ICD “viable alternative”
The subcutaneous implantable cardiac defibrillator (S-ICD) system is a viable alternative to conventional ICD systems for selected patients, results from a Dutch experience have shown.
Resynchronisation therapy shows heart failure benefit in AF patients
In patients affected by permanent atrial fibrillation (AF), cardiac resynchronisation therapy (CRT) proved superior to conventional right ventricle apical pacing in reducing the clinical manifestations of heart failure, a new study presented at Heart Rhythm 2011 has shown.
Goals for the Heart Rhythm Society
As the 2011-2012 president takes office, Bruce L Wilkoff speaks about his goals for the Heart Rhythm Society.
Hein Heidbuchel
Hein Heidbuchel, director of Electrophysiology at the University Hospital Leuven, spoke to Cardiac Rhythm News about his career, influences and proudest moments. He also described the innovations that shaped his career, new technologies and EP education.
Cameron to spend US$107 million on FDA trial and manufacture of...
The S-ICD system (Cameron) is the only implantable defibrillator that does not require electrical wires in the heart. This system is implanted using a completely subcutaneous procedure that leaves the heart and blood vessels untouched and intact.
St. Jude Medical launches visualisation system to improve EP lab workflow
VantageView system includes a 56 inch high-definition monitor that can display up to eight video images simultaneously.
Baxter launches first ready-to-use IV amiodarone
Baxter International launched Nexterone (amiodarone HCl) premixed injection, the first and only ready-to-use premixed intravenous bag version of the antiarrhythmic agent amiodarone in the United States.
Sunshine Heart completes feasibility study for fully implantable C-Pulse Heart Assist...
The C-Pulse system is an investigational device designed to relieve the symptoms of heart failure, such as shortness of breath and reduced mobility, through the use of counter-pulsation technology.
New study shows remarkably high survival rates of sudden cardiac arrest...
Survival at exercise facilities was 50%, compared with 36% observed for sudden cardiac arrest occurring in non-exercise public indoor locations. The study was presented at Heart Rhythm 2011, the Heart Rhythm Society's 32nd Annual Scientific Sessions
Boston Scientific begins international launch and first implants of next-generation devices...
Energen and Punctua cardiac resynchronisation therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs) are the world's smallest and thinnest high-energy devices to treat heart failure and sudden cardiac death and offer excellent longevity.
Medtronic announces FDA clearance and first patient procedure with the Achieve...
Achieve is an intra-cardiac electrophysiology diagnostic catheter that can be used to assess pulmonary vein isolation when treating paroxysmal atrial fibrillation (PAF). The first patient procedure in the United States using this catheter was performed by Robert Kowal, electrophysiologist at the Baylor Heart & Vascular Hospital in Dallas, USA.
New AF ablation technologies: useful tools or just expensive toys?
Fiorenzo Gaita, Università degli Studi di Torino, Turin, Italy, spoke to Cardiac Rhythm news about the real impact of fluoroscopy, intracardiac echocardiography and virtual 3D electro-anatomic mapping in atrial fibrillation ablation.
Right ventricular pacing among patients with an ICD
Alon Barsheshet, University of Rochester Medical Center, Rochester, USA, spoke to Cardiac Rhythm News on how right ventricular pacing is associated with an increased risk of heart failure.
Individualised assessment improves results of cardiac resincronisation therapy
In the first randomised clinical trial to report the benefits of using echocardiography to guide placement of pacemaker leads, researchers found that a patient-tailored approach using software to analyse left ventricle function and guide placement of lead wires can significantly boost clinical benefits from pacemakers.
More ischaemic lesions with PVAC than with other techniques
The incidence of silent cerebral lesions after pulmonary vein isolation is different depending on the technology used, a new study has shown. Atrial fibrillation patients treated with multi-electrode PVAC showed higher incidence of silent cerebral ischaemic events compared to irrigated radiofrequency and cryoballoon ablation.
Paradym RF implantable cardiac defibrillators and cardiac resynchronisation therapy devices receive...
Sorin's latest devices include SafeR and Parad+ algorithms that automatically adjust to each individual patient to minimise right ventricular pacing and inappropriate shocks.
FDA approves Attain Ability Plus and Attain Ability Straight left-heart leads...
Attain Ability Plus enables physicians to reach and maintain the target vein, providing stability in medium-to-large venous anatomies, while Attain Ability Straight allows physicians to maneuver through small cardiac veins.
No interference will occur when headphones are more than two centimetres...
The distance at which headphones cause magnetic interference with active implanted cardiac medical devices (AICMDs), such as implantable cardiac pacemakers (ICPs) and cardioverter defibrillators (ICDs), is less than previously reported, according to a research presented at Heart Rhythm 2011, San Francisco, USA.
Novel mapping system identifies sources causing atrial fibrillation
Results from the CONFIRM trial showed that a targeted, single procedure ablation at identified sources increased the long-term freedom from atrial fibrillation by 70% over the existing standard of care.
VT/VF inducibility is not a predictor of arrhythmic events in Brugada...
A multicentre, prospective study confirms lack of predictive accuracy of ventricular tachycardia/ventricular fibrillation (VT/VF) inducibility and identifies novel risk indicators for arrhythmic events in Brugada patients. Results of the PRELUDE registry were presented at Hearth Rhythm 2011, San Francisco, USA.
Douglas Packer
Douglas Packer spoke to Cardiac Rhythm News about his career, family, his presidency of the Heart Rhythm Society, new technologies and the CABANA trial.
Blazer Open-Irrigated catheter gets CE mark approval
Boston Scientific's latest radiofrequency ablation catheter is designed to treat a variety of arrhythmias and integrates Total Tip Cooling design which is intended to consistently cool the entire tip electrode during radiofrequency energy delivery.
Dabigatran etexilate recommended for approval for stroke prevention in AF patients...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of dabigatran etexilate (Boehringer Ingelheim's Pradaxa) in the member states of the European Union for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation with one or more risk factors.
ShockGuard technology receives FDA and CE mark approval
The technology, which can be used with new Unify cardiac resynchronisation therapy defibrillators and Fortify implantable cardioverter defibrillators, is designed to reduce inappropriate and unnecessary shocks for patients with these devices.
IMPROVE HF study shows adherence to outpatient quality measures associated with...
Compliance with the implantable cardioverter defibrillator process measure in eligible patients was associated with 38% lower odds of mortality over two years, and cardiac resynchronisation therapy process measure compliance was associated with 36% lower odds of mortality.
Chinese cardiac rhythm management device market forecast to grow to US$650...
Greater health care expenditure supported by robust economic growth will lead to nearly 13% annual growth in the market for pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy devices in China, according to Millennium Research Group.
Biosense starts enrolment for the REVOLUTION study for the treatment of...
REVOLUTION is a prospective, multicentre, non-randomised clinical study for the evaluation of a multi-electrode pulmonary vein isolation system used to treat paroxysmal atrial fibrillation.
Advanced Cardiac Therapeutics initiates first-in-man CE mark trial to study new...
The Tempasure system is the world's first radiofrequency cardiac ablation catheter to offer both saline irrigation and temperature-sensing technology for the treatment of atrial arrhythmias.
New stretchable device promises to make ablation simpler
The new tool has all necessary medical devices printed on a standard balloon catheter: a device for eliminating damaged tissue using heat, temperature and pressure sensors, a light-emitting diode (LED) and an electrocardiogram sensor.
Does moderate alcohol consumption increase the risk of atrial fibrillation?
Even moderate alcohol consumption can lead to the development of atrial fibrillation, according to researchers from the University of Tsukuba, Institute of Clinical Medicine, Mito, Japan.
Atrial fibrillation and dementias
Jared Bunch, cardiologist and electrophysiologist, Intermountain Medical Centre, Utah, USA, explained to Cardiac Rhythm News how atrial fibrillation is independently linked to memory impairment, cognitive decline, and general dementia.
FDA approves Consulta and Syncra cardiac resynchronisation therapy-pacemaker (CRT-P) systems
Medtronic's CRT-P systems are the first to offer exclusive Optivol fluid status monitoring with complete remote follow-up for proactive heart failure management.
St. Luke’s Episcopal Hospital is among the first in the USA...
J Alberto Lopez, a physician affiliated with Texas Heart Institute at St. Luke's Episcopal Hospital, is the first in Houston and among the first in the nation to treat patients with paroxysmal atrial fibrillation with cryoablation technology.
Winthrop-University Hospital announces Long Island’s first MRI-safe pacemaker implant
Todd Cohen, director of Electrophysiology and Pacemaker/Arrhythmia Center, Winthrop-University Hospital, USA, completed the procedure and was also the lead investigator in the clinical trials that resulted in FDA approval for the Revo MRI Sure Scan (Medtronic) in February 2011.
Mount Sinai performs first US cardiac ablation using contact force-sensing catheter...
The first catheter ablation procedure was performed at the end of February by Vivek Y. Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Heart and colleagues.
No overall survival benefit for ICDs inserted within 40 days after...
Despite major advances during the past two decades in the management of patients with acute myocardial infarction, sudden cardiac death remains an important contributor to overall mortality, according to Reginald Liew, National Heart Centre, Singapore.
Cardiac resynchronisation therapy twice as effective in women
Female patients had a better result from cardiac resynchronisation therapy with defibrillator than male patients with a significant 69% reduction in death or heart failure, according to results published in the Journal of American College of Cardiology.
Achieve mapping catheter is launched in Europe
The Medtronic's mapping catheter is an intra-cardiac electrophysiology recording catheter that can be used to assess pulmonary vein isolation when treating paroxysmal atrial fibrillation.
Biotronik launches industry’s smallest implantable cardiac device programmer in Europe
Renamic is used for initial programming, reprogramming and testing of implantable pacemakers, implantable cardioverter-defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) devices after implantation.
Cardiomyocyte product exhibits protective properties against arrhythmias and halts
Administering GRNCM1 (Gerom) by injection into the heart resulted in greater resistance to induced arrhythmias, halted adverse cardiac remodeling and preserved mechanical function compared to controls.
Medtronic Foundation invests US$15 Million in multistate project to reduce sudden...
The goal of the HeartRescue Project is to improve out-of-hospital cardiac arrest survival rates by at least 50% in five years, within five pilot states in USA.
Simbionix releases innovative module for practicing transseptal puncturing
The new transseptal module offers a complete training curriculum for electrophysiologists on the Angio Mentor, allowing physicians a safe environment in which to train until proficient in the essential tasks they are required to perform.
The European cardiac rhythm management, electrophysiology and ablation market valued at...
These markets could reach over €4.4 billion by 2017, according to a report published by iData Research.
CardioFocus gets $30.6 M in private financing
Proceeds support initiation of US pivotal trial and expansion of European commercialisation of the CardioFocus' Endoscopic Ablation System.
Peter Schwartz
Peter Schwartz tells Cardiac Rhythm News about loving his research, being best man at a patient's wedding and having an article about golf published in a medical journal.
Biotronik announces start of the NORDIC ICD clinical trial
This trial investigates whether implantable cardioverter defibrillator (ICD) implantation without an intraoperative defibrillation test is noninferior to ICD implantation with intraoperative defibrillation testing.
Endosense completes enrolment in EFFICAS I clinical study
EFFICAS I is a 45-patient, single-arm, prospective, multicentre European clinical trial designed to demonstrate the correlation between contact forces applied during pulmonary vein isolation and atrial fibrillation treatment efficacy at three months.
Dabigatran added to recommendations for treating AF
The newly approved drug dabigatran is an alternative to warfarin to help prevent dangerous blood clots in patients with atrial fibrillation (AF), according to updated guidelines from the American College of Cardiology, American Heart Association and the Heart Rhythm Society.
The World Heart Federation, Sanofi-aventis and Boehringer Ingelheim announce collaboration on...
The campaign aims to promote education around the risks associated with AF as well as highlight the importance of early diagnosis and comprehensive management to maximise patient outcomes.
Cardiac resynchronisation and the benefits of a quadripolar LV lead
Ali Al-Sayegh, cardiologist at the Chest Diseases Hospital, Kuwait, explains how cardiac resynchronization therapy has better outcomes using quadripolar LV leads.
Apixaban superior to aspirin in reducing stroke and systemic embolism in...
Bristol-Myers Squibb and Pfizer announced the full results of the AVERROES study of apixaban in The New England Journal of Medicine.
Pulmonary vein isolation with cryoballoon comparable to radio frequency ablation
The Arctic Front Cryoballoon from Medtronic is safe with very low incidence of pulmonary vein stenosis and no cryo-related left atrial perforation and low thrombogenic risk. Results were presented by Wyn Davies, London, UK, at the annual Europe AF meeting in London, UK.
FDA approves first pacemaker designed to work safely during some MRI...
None of the 211 patients who underwent a magnetic resonance imaging exam during the clinical trial of Revo MRI SureScan pacing system experienced an MRI-related complication, the FDA stated.
Apixaban reduces stroke by more than 50% in AF patients
In atrial fibrillation (AF) patients unsuitable for a vitamin K antagonist, apixaban reduces stroke by more than 50% compared to acetylsalicylic acid without a significant increase in major bleeding.
RE-LY sets benchmark for trials of thromboprophylaxis in AF
A total of 20,240 patients with non-valvular atrial fibrillation (AF) were assessed for eligibility in the RE-LY trial. Gregory Lip, University of Birmingham, UK, presented the results of the RE-LY sub-studies at the annual Europe AF meeting in London.
Biotronik launches new pacing system analyser in Europe
Reliaty is used to ensure adequate lead placement of implantable pacemakers, Implantable Cardioverter-Defibrillators (ICDs) and Cardiac Resynchronisation Therapy (CRT).
Endosense and Siemens Healthcare work together in development project to improve...
The main goal of the shared development project is to achieve an improved visualisation of catheter-tip-to-tissue contact force within a three-dimensional anatomic heart model during catheter ablation procedures.
Rare severe liver injury risk warning added to dronedarone labels
The new drug's label warning is due to two cases of acute liver failure leading to liver transplant in patients treated with this heart medication.
Boston Scientific to acquire Atritech
The Atritech Watchman left atrial appendage closure device is an alternative to warfarin for patients experiencing atrial fibrillation who are at high risk for stroke.
First clinical ablation cases in the EU using the Thermocool Smarttouch...
The CE-marked Thermocool Smarttouch catheter provides an important new parameter for the mapping and ablation of complex cardiac arrhythmias, such as atrial fibrillation.
TOCCASTAR IDE study of TactiCath force-sensing ablation catheter (Endosense) is launched
TOCCASTAR will explore a new catheter ablation treatment option for patients who have symptomatic paroxysmal atrial fibrillation and who are resistant or intolerant to at least one Class I-IV anti-arrhythmic drug.
CE Mark and first human case for Vdrive robotic navigation system
Vdrive combines magnetic navigation with the Odyssey information management system to bring precise control during catheter-based electrophysiology procedures.
Application for rivaroxaban in AF patients submitted to the FDA
Clinical studies on rivaroxaban have shown no requirement for routine laboratory coagulation monitoring, and limited risk for food and drug interactions.
Repeat ablation procedures provide “acceptable” long-term relief for AF patients
Five-year follow-up results from a study of catheter ablation for atrial fibrillation shows long-term success increases when outcomes are measured after the last ablation procedure.
Panos Vardas
Panos Vardas from Greece, president of the European Heart Rhythm Association (EHRA) and president-elect of the European Society of Cardiology (ESC) spoke to Cardiac Rythm News about his passion for Cardiology, his biggest achievements and plans to lead the ESC.
Many patients with ICDs do not meet criteria for use
Study published in the JAMA also showed that these patients had a significantly higher risk of in-hospital death than those who met criteria for receiving an ICD.
FDA approves cryoballoon ablation treatment for paroxysmal AF
The Arctic Front Cardiac CryoAblation Catheter system is the first and only Cryoballoon in the United States indicated for the treatment of drug refractory paroxysmal atrial fibrillation.
Mayo Clinic first in USA to use newly approved FDA technology...
"This approach provides a single ablative means of eliminating problematic atrial fibrillation in patients who failed drug therapy," said Douglas Packer, cardiologist at Mayo Clinic.
CMS approves electrophysiology physician specialty code
"The new physician specialty code is a major achievement for the Heart Rhythm Society and the field of electrophysiology," said Douglas L Packer, president of the Heart Rhythm Society.
First patient enrolled in trial of the CorMatrix ECM for pericardial...
Prospective, multicentre, randomised trial will enrol more than 400 patients at up to 15 cardiac surgery sites in the USA.
St Jude Medical advances integration of EP lab equipment with launch...
Advanced suite of EnSite Velocity System product offerings streamline workflow and provide physicians with improved efficiency.
New trial studies link between stroke and atrial fibrillation
The CRYSTAL AF trial will enrol approximately 450 people who have been diagnosed with a cryptogenic stroke across 55 centres.
Analysis of patients monitored by the Latitude System shows relative reduction...
The analysis also showed that heart failure patients who transmitted weight and blood pressure data via the system experienced an additional 10% reduction in the risk of death.
European economic analysis shows cost benefit of CRT in mild heart...
"CRT not only helps keep less sick heart failure patients out of the hospital more, but it is also a more cost-effective treatment approach than many other therapeutic options currently available," said Cecilia Linde, Stockholm, Sweden.
Phase III ENGAGE AF-TIMI 48 study of edoxaban completes enrolment
More than 21,000 patients were enrolled in the largest clinical study and were randomised to receive the factor Xa inhibitor or warfarin.
Symptoms and quality of life improved with catheter ablation in AF...
Patients who were treated with catheter ablation reported fewer symptoms and improved quality of life than patients treated with anti-arrhythmia drugs at one year.
Poor treatment of AF puts patients’ lives at risk
AF AWARE campaign calls for urgent action to improve patients' health and reduce costs to national health systems.
Implanted devices as effective in “real world” as in clinical trial...
Study published in Circulation showed that, after one year, 92% of ICD recipients and 88% of CRT-D patients were alive. Survival rates after five years were 68% for ICD and 54% for CRT-D.
Philips’ new remote pacemaker monitoring designed to improve patient compliance
New 24-hour, web-based service helps cardiologists leverage cutting-edge technology in implanted cardiac devices.
Boston Scientific announces CE mark approval and first implants for new...
Incepta, Energen and Punctua CRT-Ds and ICDs designed to advance patient care with options to expand appropriate therapy, optimise ventricular pacing and manage heart failure.
Reveal insertable cardiac monitor led to effective diagnosis and specific treatment...
Medtronic's PICTURE registry results show that device led to diagnosis and treatment for 78% of patients who experience a recurrent syncopal event.
Rivaroxaban comparable to warfarin in preventing stroke
The new drug does not increase bleeding risk among atrial fibrillation patients, according to results of the ROCKET AF trial presented at the American Heart Association's Scientific Sessions.
ASSERT study demonstrates effectiveness of implantable device monitoring in predicting stroke
Pacemaker patients who have device-detected arrhythmias are approximately 2.5 times more likely to have a stroke than patients who do not have device-detected arrhythmias.
Standard pacing therapy regulates heart pumping as well as costly tailored...
Study shows that cardiac resynchronisation therapy is as effective as two other methods that regulate the time interval between the squeezing of the heart's upper and lower chambers.
FDA approves dabigatran to prevent stroke in atrial fibrillation patients
The FDA approved on 19 October 2010 dabigatran etexilate (Pradaxa, Boehringer Ingelheim) for the prevention of stroke and blood clots in patients with atrial fibrillation.
BIOTRONIK: EchoCRT clinical trial design validated with recent publication in European...
The BIOTRONIK EchoCRT clinical trial aims to evaluate the impact of cardiac resynchronisation therapy in patients with advance heart failure.
FDA advisory committee unanimously recommends approval of dabigatran etexilate for stroke...
Dabigatran etexilate may offer patients and doctors the first new treatment option for stroke prevention in atrial fibrillation in more than 50 years.
FDA approves devices for heart failure patients
A new indication for three cardiac resynchronisation therapy defibrillators can be used for patients with an abnormality known as left bundle branch block.
FDA approves new CRT-D indication for heart failure patients
The three devices from Boston Scientific are intended to treat patients with left bundle branch block who have either mild heart failure or heart failure with no apparent symptoms.
Medtronic introduces new CareLink remote monitoring network for heart failure clinicians
System supports proactive patient care for patients at risk for worsening heart failure.
Vernakalant approved in Europe for rapid conversion of recent onset AF
Intravenous formulation of vernakalant can offer physicians, patients and hospitals an important therapy option to use for the rapid treatment of recent-onset atrial fibrillation.
Hansen Medical signs agreement to integrate its Sensei X CoHesion 3-D...
Agreement is part of deal to promote new products utilising new complementary technologies tackling heart rhythm disorders.
NICE guidance gives people living with AF more treatment options
Technology appraisal recommends the use of dronedarone in treating Atrial Fibrillation under specific conditions.
New imaging method can aid in planning implantable cardiac defibrillator placement
Study shows molecular imaging can play an important role in diagnosing risk in cardiovascular patients, according to researchers in Japan.
New defibrillator may offer 24/7 surveillance without touching the heart
Cameron Health's S-ICD device promises to reduce the delivery of "unnecessary shocks".
Spectranetics SLS II receives Japan’s reimbursement approval
Laser Sheath to become company's first-ever Japanese export.
NICE publishes final draft guidance on dronedarone treating AF
Report suggests drug should only be considered as treatment option for people who have additional cardiovascular risks.
CLARITY-AF patient recruitment reaches double figures
Over ten patients enrolled in first-ever multicentre randomised trial comparing atrial fibrillation ablation devices.
MultiSENSE trial enrolment gets underway
Study has been designed to evaluate multiple physiologic sensors in cardiac resynchronisation therapy defibrillators.
Telemonitoring benefits heart failure patients’ everyday lives
Ryszard Piotrowicz, head of Department of Cardiac Rehabilitaion and Noninvasive Electrocardiology, National Institute of Cardiology, Warsaw, explains the advances in the provision of cardiac rehabilitation to heart failure patients.
Biotronik will launch the Lumax DX system in Europe in the...
Lumax DX system pioneers the use of 'Smart Detection' in monitoring atrial activity.
St Jude Medical announces European launch of industry’s first quadripolar pacing...
The Promote Quadra CRT-D should be considered "a new standard of care" says Wolfgang Kranig.
Boston Scientific announces availability of new connector system designed to simplify...
The company release a new cardiac rhythm management connector system designed to simplify implant procedure.
Biotronik adds new Reocor external pacemaker to its product portfolio
Reocor offers extended battery service times of up to 25 days.
Stereotaxis and Siemens Promote Integrated Odyssey Solutions
Live demo highlights the benefits of integrated technology.
Lifevest selected as one of the top five medical devices of...
Dot Medical hails the Wearable Defibrillator as one of "technologically exceptional".
Worldwide survey shows ablation works without drugs in most cases
Riccardo Cappato, Centre of Clinical Arrhythmia and Electrophysiology, Policlinico San Donato, Milan, makes his case following the second global survey on catheter ablation.
More strategy, fewer shocks
Lessons in programming to be learnt from findings, claims Bruce Wilkoff.
Entirely subcutaneous ICD treats ventricular arrhythmias
Gust H Bardy believes S-ICDs to prove a "viable alternative" to the transvenous system.
Twelve-month data from TOCCATA study reinforce clinical benefit of force sensing
Results show the TactiCath to be an effective ablation catheter.
Josep Brugada
Josep Brugada speaks to Cardiac Rhythm News about his career, his proudest moments and his association with Barcelona FC.
Douglas Packer takes office as new HRS president
Richard L Page hands over to Packer at HRS ceremony.
NIH funds innovative electroactive polymer based steerable catheter for the treatment...
The US$2.2 million grant will support the design and commercialisation of SPS's revolutionary steerable cardiac mapping and ablation catheter technology.
STOP-AF shows cryoablation prevents atrial fibrillation better than drugs
Professor Douglas Packer presents the results of two clinical trials conducted using the cryoablation technique.
CABANA pilot shows ablation more effective in preventing AF recurrence
Professor Douglas Packer presents the results of the pilot study at the American College of Cardiology Scientific Sessions.
NICE’s draft guidance does not recommend dronedarone for AF
NICE chief executive finds dronedarone "less effective" compared to existing AF treatments.
Bruce L Wilkoff
Bruce L Wilkoff, The Cleveland Clinic, Cleveland, USA, has been involved in the development of several cardiac devices. He tells Cardiac Rhythm News which of them he considers the most important.
St Jude Medical announces European launch of USB Cellular adaptor for...
New USB adaptor allows patients using Merlin@home transmitter to transfer data to their physician over mobile phone networks.
St Jude Medical announces European approval of smaller, higher power ICD...
The Fortify and Unify devices get CE Mark; expected to be universally available by the end of the year.
Cambridge Heart completes development of new MTWA Module
CEO praises technological advances in the module's development.
Sorin announces market release and first implant of next-generation CRT-D
FDA approval given for the Paradym CRT Model 8750.
Physio-Control LIFEPAK battery fault
Physio-Control admits there may be a battery problem with the Lifepak 20/20e defibrillator/monitor.
Medtronic’s Ensura MRI SureScan Pacing System receives CE mark
New option in second-generation pacing system available in select European geographies features exclusive technology and allows access to critical diagnostic tool.
MADIT-CRT data show women received greater benefit from CRT-Ds than men
The sub-analysis demonstrated that both men and women experienced benefit from CRT but women experienced a 70% reduction in heart failure events compared to a 35% reduction for men.
Endosense launches next generation TactiCath force-sensing catheter
The second generation product includes an elegantly enhanced catheter along with a feature-rich supporting system called the TactiSysTM.
CLARITY will compare efficacy, safety and efficiency of the NaviStar ThermoCool...
Biosense Webster announced on 9 April 2010 that it has obtained its first Ethics Committee approval for the study in patients with paroxysmal atrial fibrillation.
Boston Scientific to resume distribution of Cognis CRT-Ds and Teligen ICDs...
Boston Scientific has received FDA clearance for the two validated manufacturing changes affecting all of its CRT-Ds and ICDs.
Guidant pleads guilty for not reporting defibrillator safety problems to FDA
Medical device manufacturer will pay criminal penalty of more than US$296 million for violations of the US Federal Food, Drug and Cosmetic Act.
Multaq receives positive recommendation by NICE in new appraisal consultation document
The NICE appraisal committee's preliminary recommendation is to endorse Multaq as a first choice therapeutic option after beta-blockers for non-permanent AF patients.
FDA Advisory Panel recommends expanded CRT indication for heart failure
The panel unanimous decision extends resynchronisation therapy for asymptomatic and mild heart failure patients based on landmark MADIT-CRT trial.
FDA panel recommends approval of Medtronic’s Revo MRI SureScan Pacing System
If approved, Revo MRI has the potential to be the first FDA-approved pacing system designed for use in the MRI setting.
Medtronic announces next-generation pacing system for use in MRI
Advisa DR MRI SureScan, the most advanced pacing system from Medtronic that combines MRI compatibility with exclusive pacing technology, is now available in Europe.
Promising results for cryoablation presented at ACC congress
Safety and effectiveness trial evaluated the Medtronic Arctic Front Cardiac CryoAblation Catheter System for the treatment of paroxysmal atrial fibrillation.
New study uncovers gender disparity in ablation treatment and outcomes for...
Study published in HeartRhythm Journal shows female patients undergo catheter ablation less often and experience more complications than males
More centres perform ablation for persistent and permanent AF
New observations from the Second Worldwide Survey on AF Ablation showed that more procedures are being offered every year.
Clopidogrel and dabigatran are alternatives to warfarin
Results of the ACTIVE A and RE-LY trials were presented by Stuart Connolly, McMaster University, Hamilton, Canada, at the Boston AF Symposium.
Trials beginning this year will compare AF ablation devices
An overview of clinical trials on AF ablation devices seeking FDA approval was presented by Hugh Calkins, Johns Hopkins Hospital, Baltimore, USA, at the Boston AF Symposium.
St Jude Medical announces sponsorship of SCD-HeFT 10-year Follow-up Study
New study will revisit patients from the groundbreaking SCD-HeFT trial to collect long-term data regarding the efficacy of ICDs in heart failure patients.
Biotronik and Endosense sign international exclusive distribution partnership
Under the terms of the agreement, Biotronik will be the exclusive distributor of the TactiCath in all major markets outside of the United States, Japan and Asia.
Stereotaxis is notified of the FDA approval of an additional magnetic...
The FDA also approved all magnetic catheters for use with newly increased field strength for magnetic navigation.
Draft NICE guidance unable to recommend dronedarone for atrial fibrillation
"The evidence provided to the independent appraisal committee indicates that dronedarone is less effective and costs considerably more than existing treatments for controlling AF," the agency wrote.
New Biotronik’s leadless cardiac monitoring device is implanted
Diagnostic device for complete wireless remote patient monitoring is compatible with the Biotronik Home Monitoring.
Spectranetics announces FDA clearance of VisiSheath Dilator Sheath
Enhanced visibility and performance features help physicians dilate scar tissue surrounding problematic cardiac leads requiring removal.
Dronedarone approved in the European Union for patients with atrial fibrillation
Multaq, developed by Sanofi-aventis, is the first new anti-arrhythmic drug to be approved in Europe in the last 10 years.
Boston Scientific’s most advanced devices to treat heart failure and sudden...
Cognis cardiac resynchronisation therapy defibrillator and Teligen implantable cardioverter defibrillator are the world's smallest and thinnest high-energy devices.
Lead management: Beyond see one, do one
Charles Love, The Ohio State University, analyses updates and highlights on issues related to lead management and extraction.
Fred Morady
Fred Morady spoke to Cardiac Rhythm News about his influences, areas of research, and activities outside medicine: building furniture at home and downsizing to a Cessna 182.
Call for more studies on new agents for atrial fibrillation
We have many drugs available to us that could eventually come to clinical trials, but there are very few studies ongoing at the moment, John Camm said at the Venice Arrhythmias symposium.
Analysis of ATHENA shows stroke reduction with dronedarone
Patients receiving dronedarone for atrial fibrillation on top of adequate antithrombotic medication presented a significantly lower incidence of stroke, according to Stefan Hohnloser.
New Lynx robotic irrigated ablation catheter is presented at Venice Arrhythmias
Hansen Medical showcased the small, flexible irrigated ablation catheter for the first time. CE mark is expected in the first half of 2010.
MADIT-RIT enrols first patients
The clinical trial, sponsored by Boston Scientific, was designed to determine which programming strategy best minimises the occurrence of unnecessary therapy in ICD and CRT-D patients.
Paroxysmal and non-paroxysmal AF patients benefit from repeat catheter ablation
Isolation of the pulmonary vein antrum and the superior vena cava using intracardiac echocardiography and circular mapping can achieve encouraging cure rates.
Arthur Moss receives Golden Lionel Award in Venice
Cardiologist, professor of Medicine at the University of Rochester Medical Center, USA, led studies that have changed medical guidelines.
St Jude Medical launches cardiac rhythm management devices in Australia
The Current Accel ICD, AnalyST Accel ICD, Promote Accel CRT-D, Durata high-voltage cardiac lead, and the SJM Confirm implantable cardiac monitor are now approved in the country.
Dronedarone recommended for approval in the European Union
The European Medicines Agency has adopted a positive opinion recommending the grant of a marketing authorisation for Multaq (dronedarone, 400mg tablets).
“MADIT-CRT shows compelling results”
Asymptomatic or mildly symptomatic cardiac patients randomised to an implanted CRT-D have a 34% lower risk of heart failure or death than those receiving a standard ICD.
Cost-effectiveness of atrial fibrillation catheter ablation
Panos E Vardas, president of the European Heart Rhythm Association, analyses the trend on expanding the existing indications and usage of ablation.
Physio-Control receives market approval from Health Canada for Lifepak 15 monitor/defibrillator
The Lifepak 15 provides the widest range of energy dosing up to 360 joules, and the broadest selection of monitoring options available.
Health leaders issue recommendations to improve AF management
AF Stat Call to Action for Atrial Fibrillation report cites limited understanding, disconnected dialogue and uncoordinated care as key barriers to improved outcomes.
Mount Sinai first in nation to ablate AF using new visually-guided...
Physicians at The Mount Sinai Medical Center in New York became the first in the US to ablate atrial fibrillation using the "Endoscopic Ablation System" manufactured by CardioFocus.
Home monitoring reduces clinic visits and provides rapid detection of events
Data from the studies TRUST; REFORM and ISMOS have demonstrated that the Biotronik Home Monitoring is reliable and effective in managing device patients remotely.
“It is safe to use, has high efficacy and reduces healthcare...
Niraj Varma and Thomas Vogtmann both led studies on the Biotronik Home Monitoring System. They spoke to Cardiac Rhythm News at the ESC 2009 Congress in Barcelona, Spain.
Study shows fluid monitoring more accurate than weight measures for heart...
Results showed that Medtronic OptiVol Fluid Status Monitoring predicted 76% of future heart failure events as compared to only 23% detected by weight monitoring alone.
How to improve quality of care in electrophysiology in Europe
Jose L Merino, Hospital Universitario La Paz, Madrid, Spain, analyses the implementation of actions to guarantee quality and qualification in cardiac rhythm management.
Early research shows CRT may benefit patients with ejection fractions above...
A retrospective analysis from the PROSPECT study suggests the potential for CRT to benefit more than 1 million heart failure patients worldwide.
St Jude Medical announces FDA approval of EnSite Velocity Cardiac Mapping...
Next-generation cardiac mapping system gives physicians the ability to increase procedural efficiency and speed for treating irregular heart rhythms.
Watchman: Alternative to long-term warfarin therapy
An article published in The Lancet reports that patients with AF at risk of stroke could be offered percutaneous closure of the left atrial appendage instead of long-term warfarin therapy.
T-wave morphology parameters open new door to cardiovascular mortality prognosis
New research reveals T-wave morphology parameters contain predictive value for mortality in the general population, independent of other clinical risk factors.
Copy of FDA approves dronedarone for patients with atrial fibrillation or...
Approved to reduce the risk of cardiovascular hospitalization, Multaq will be launched this summer in the US by Sanofi-aventis.
New wireless pacemaker helps heart patients stay in touch
Doctors at Wake Forest University Baptist Medical Center's Heart Center have implanted one of the first wireless pacemakers in the US.
Edoxaban: Next generation oral anticoagulant under investigation
New treatment could offer further option in addition to current standard of care in thromboembolic disease in atrial fibrillation patients.
RE-LY: Dabigatran reduces incidence of stroke and systemic embolism
The anticoagulant dabigatran is more effective than warfarin in the prevention of stroke in patients with atrial fibrillation, according to results from the RE-LY study.
XPECT: Monitoring AF with a minimally invasive device
John Camm, London, UK, analyses the first MRI approved insertable cardiac monitor (ICM) featuring an automatic AF detection algorithm.
CardioFocus receives CE mark for AF ablation catheter
The device incorporates a micro-endoscope and light energy fibres to give physicians the capacity to see within the heart and visually direct the application of energy through a catheter.
PreSCD II Registry shows ICDs lead to 44% reduction in mortality...
The mortality reduction trend was also observed in high-risk patients with severely reduced heart function.
Riccardo Cappato
Riccardo Cappato, from Milan, Italy, spoke to Cardiac Rhythm News about his career, advances in cardiac rhythm management, and his passion for crime fiction.
deCODE discovers second common genetic risk factor for AF and stroke
The new sequence is in the ZFHX3 gene on chromosome 16q22, and the one third of people of European descent who carry one copy are at 20% greater risk of AF and stroke.
Mixed evidence on use of radiofrequency catheter ablation for AF
Report funded by the US Agency for Healthcare Research and Quality calls for more research on the effect of catheter ablation on quality of life.
European approval for the Latitude Patient Management System
Boston Scientific's wireless system remotely monitors patients with implantable cardiac devices and can detects clinical events between scheduled physician visits.
AF linked to increased hospitalisation in heart failure patients
Patients with atrial fibrillation, common in those with advanced chronic heart failure, have an increased risk of hospitalisation due to heart failure.
Heart electrical conduction abnormality may pose cardiovascular risks
Disorder previously believed to be benign is associated with an increased risk for atrial fibrillation, implantation of a pacemaker or death.
Europace 2009 calls for more remote monitoring of implantable devices
More European countries need to embrace the remote monitoring of cardiac implantable devices, rather than offering face to face clinic visits, concluded a press briefing at Europace 2009.
Big disparities in the treatment of arrhythmias across Europe
Latest statistics on pacemakers and implantable cardiac devices were presented at Europace 2009. Germany has one of the highest ICD implant rates in Europe.
Medtronic receives CE mark for second generation MRI pacemaker
Advisa DR MRI SureScan Pacing System gives pacemaker patients safe access to critical diagnostic tool.
Mayo Clinic receives US$48 million in grants to study catheter ablation...
The CABANA trial is designed to determine whether catheter ablation is more effective than drug therapy for the treatment of atrial fibrillation.
AF AWARE calls for greater awareness and better education on atrial...
Survey shows many doctors find the management of atrial fibrillation difficult and patients are unaware of risks, complexities and treatment.
New MADIT II data analysis shows long-term survival benefit for implantable...
At eight years, one life is saved for every six patients who receive an ICD, according to data presented at Heart Rhythm 2009.
Expert consensus statement on the catheter ablation of ventricular arrhythmias is...
State-of-the-art review of catheter ablation of VT by an international panel of experts was released during the Heart Rhythm Society's 30th Annual Scientific Sessions.
Long-term Medtronic device registry shows how implantable devices work in clinical...
OMNI study showed that one out of six patients with defibrillators to prevent sudden cardiac arrest received lifesaving medical therapy within a period of two years following their implant.
Weight-loss supplements may cause life-threatening cardiac complications or death
Study published in the HeartRhythm Journal reveals hidden heart health risks associated with ingredients found in diet pills.
Medtronic announces trial of therapy for closure of the left atrial...
Study in the USA will evaluate the Cardioblate Closure, a device intended to occlude the LAA permanently without introducing man-made materials into the blood stream.
FDA approves new Medtronic left heart lead for CRT devices
Attain Ability lead is the first to use NASA technology in this kind of implantable medical device.
Endosense receives CE mark for TactiCath force-sensing ablation catheter
Approval was granted based on select data submitted from the TOCCATA clinical study, which was performed by 17 experienced investigators at eight European centres.
LExICon study shows laser assisted lead removal effective
Spectranetics laser sheath (SLS II) demonstrated 97.7% clinical success rate in removal procedures performed between January 2004 and December 2007.
Mild heart failure: The REVERSE results
Dirk J van Veldhuisen analyses the findings on the use of CRT for heart failure patients classes I and II and how the results will impact in future studies.
One in 1,000 risk of death from catheter ablation for AF
Analysis of data from 162 centres worldwide between 1995 and 2006 showed that tamponade caused the highest number of fatalities, followed by stroke and atrioesophageal fistula.
Researchers identify stroke predictors in black patients
Predictors of atrial fibrillation might offer physicians a better way to prevent stroke in blacks, according to a new study performed in Winston-Salem, USA.
Voice response system useful for monitoring anticoagulant patients
Interactive voice response systems may help improve monitoring of patients taking anticoagulants such as warfarin while reducing the workload of clinical staff.
UK has its 500,000th pacemaker implanted
The landmark procedure was performed at St George's Hospital, the same London institution that undertook the first implant more than 50 years ago.
Robotic vs. magnetic navigation
Drs Andrea Natale and Carlo Pappone debate the merits of magnetic (Stereotaxis) or robotic (Hansen Medical) navigation for catheter ablation of atrial fibrillation.
FDA panel votes seven to five to recommend approval of the...
Device used for closure of the left atrial appendage may be an alternative to warfarin therapy for the prevention of stroke in patients with nonvalvular atrial fibrillation.
St Jude Medical announces CE mark approval of Merlin.net
Web-based system, Merlin.net Patient Care Network combines tools that can help physicians monitor implanted cardiac devices patients and improve clinic efficiency.
Big men more susceptible to atrial fibrillation
Study shows that older men who were big during their 20s face an increased risk of suffering from atrial fibrillation.
Certified “electricians” best deal with electrical problems
Cardiologist's editorial in JAMA says certified "heart electricians" should implant cardioverter defibrillators.
Stanley Nattel
Stanley Nattel, Montreal, Canada, spoke to Cardiac Rhythm News about his career, the challenges facing electrophysiology, and the future of the research on drugs for arrhythmias.
St Jude Medical’s implantable defibrillators receive CE mark
AnalyST Accel and Current Accel provide new alerts and insight into cardiac conditions such as atrial fibrillation and ischaemia.
Valsartan fails against atrial fibrillation recurrence
Study showed that atrial fibrillation recurred in 51.4% of patients in the drug group, as compared with 52.1% in the placebo group.
Advances in ablation of long-standing persistent AF
Matthew Wright, Hopital Cardiologique du Haut-Levaque, Bordeaux-Pessac, France talks about techniques and developments in catheter ablation for persistent AF.
Merlin.net patient care network wins Medical Design Excellence Award
The St Jude Medical's Merlin.net patient care network has received a 2009 Medical Design Excellence Award.
Novel imaging technique may predict outcomes in AF patients
Researchers have found that delayed-enhancement magnetic resonance imaging holds promise for predicting treatment outcomes and measuring disease progression.
Sorin announces European market release of the Esprit pacemaker
World's smallest pacemakers feature algorithms dedicated to patient safety and proven therapies.
Registry will assess the state of anticoagulation therapy for AF
Boehringer Ingelheim has announced it plans to launch REAL-AF, a USA based registry to evaluate patterns in the present practice of anticoagulation in 2,500 patients.
Home Monitoring with traffic light is launched globally
The new Biotronik Home Monitoring integrates an intelligent traffic light system that simplifies remote monitoring of patients with implantable cardiac devices.
Novel device cuts stroke risk in patients with atrial fibrillation
The Watchman, an expandable nitinol cage which blocks blood clots that typically form in the left atrial appendage, may offer alternative to blood-thinning medications.
Targeted drug therapy prevents exercise-induced arrhythmias
Researchers reported that flecainide can prevent potentially lethal arrhythmias in patients with a specific type of exercise or stress-induced arrhythmia disorder called CPVT.
Angiography could avoid coronary lesions after ablation in youngsters with a...
Study assessed the incidence of coronary artery injury early after catheter ablation for supraventricular tachycardias in children.
Chronic kidney disease increases risk of thromboembolism in AF
Study shows that knowing the level of kidney function and presence of proteinuria may improve decision making about the use of antithrombotic therapy.
Final patient completes treatment in the RE-LY study
Trial compares dabigatran etexilate with warfarin for the prevention of stroke and non-CNS systemic embolism in patients with atrial fibrillation.
UK’s Arrhythmia Awareness Week is launched
Event to be held with the World Heart Rhythm Week, 8-14 June 2009, aims to provide information on diseases and encourage routine pulse checks.
FDA’s committee recommends approval of dronedarone for AF
Efficacy of the new drug was assessed in the ATHENA trial, published in the 12 February 2009 issue of the New England Journal of Medicine.
FDA approves new features in Merlin.net
St Jude Medical's patient care network for implantable cardiac devices introduces Spanish language capabilities, new patient scheduling tools and expanded alerts for physicians.
Increasing use of ablation to treat atrial fibrillation
American report says number of catheter ablation procedures for treating atrial fibrillation will fuel revenues in the electrophysiology ablation catheter market over the next five years.
AF think tank: A move for the national registry in the...
Program will discuss areas related to ablation, cardiac safety and a registry of procedures and outcomes from the clinical, regulatory, and industry perspectives.
Link between diabetics who have AF and risk of heart problems...
The ADVANCE trial has shown that type 2 diabetes patients who had AF at the start of the study had a 61% increased risk of dying from any cause.
Test successfully identifies life-threatening heart condition
A study led by investigators from Boston has demonstrated that a new immunohistochemical test is reliable in diagnosing arrhythmogenic right ventricular cardiomyopathy.
New technology used to treat atrial fibrillation
The Texas Cardiac Arrhythmia Institute, Austin, became the first in the United States to utilise the long-awaited NaviStar ThermoCool Catheter.
Rhythm abnormality of unknown origin predicts sudden death risk
Researchers conducting a large study on sudden cardiac death were surprised to discover that a heart rhythm abnormality increased risk fivefold among patients with coronary artery disease.
Abandoned leads do not pose a risk to ICD patients
A new study revealed that abandoning a nonfunctioning lead in an implantable cardioverter defibrillator patient is safe and does not pose a clinically significant risk of complication.
Implantable defibrillators, pacemakers affected by MP3 headphones
Headphones for MP3 players placed within an inch of pacemakers and implantable cardioverter defibrillators may interfere with these devices, according to research presented at the AHA's Scientific Sessions 2008.
British investigators demonstrate safety of AF ablation in the elderly
Investigators from The Heart Hospital, University College London, have demonstrated that atrial fibrillation ablation in older patients can be achieved safely with similar complication risks.
Novel imaging approach may assist in predicting success of treatment for...
University of Utah researchers have developed a magnetic resonance imaging-based method for detecting and quantifying injury to the wall of the heart's left atrium in patients who have undergone a procedure to treat atrial fibrillation.
New imaging approach may assist in predicting success of treatment for...
University of Utah researchers have developed a magnetic resonance imaging-based method for detecting and quantifying injury to the wall of the heart's left atrium in patients who have undergone a procedure to treat atrial fibrillation.
Robotic navigation systems in the spotlight
The use of robotic navigation in procedures to treat heart rhythm problems such as atrial flutters is gaining popularity as technology becomes more and more advanced.
Genetic information can improve administration of anticoagulant
A study from the International Warfarin Pharmacogenetics Consortium confirms that using a patient's genetic information can make it easier to get the warfarin dose right.
Revolutionising access to the heart
"Epi-needle access system" developed in the University of Virginia allows physicians to go through the fluid-filled sac to the epicardium without entering the heart.
QT and heart rate variance predict risk of arrhythmia in men...
New study published in the February edition of the HeartRhythm Journal confirms gender impacts risk of arrhythmias.
John Camm
John Camm talks about his many career achievements including his highlights, research activities and involvement in patient groups.
Cryoablation appears effective for paroxysmal but not persistent AF
The novel cryoballoon device (Arctic Front, Cryocath) appears safe and effective for patients with paroxysmal atrial fibrillation (AF), but not for those with persistent AF, according to German researchers.
ATHENA data suggest decrease in stroke risk with dronedarone for AF
Results from a post-hoc analysis of the data from the ATHENA trial show that dronedarone reduces stroke risk in patients with atrial fibrillation.
AF-CHF trial results published
Results from the first trial to examine rhythm vs. rate control in heart failure patients with atrial fibrillation have been reported in the New England Journal of Medicine.
Corindus CorPath “safe” in pilot study
The Corindus CorPath system, a robotic catheter manipulation platform, was discussed by Dr Peter Fitzgerald, Center for Cardiovascular Technology, Stanford University Medical Center, at the TCT meeting in October.